Skip to main content Skip to navigation

Ivosidenib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026 Medically reviewed by: RxHarun Orthopedic Specialist Doctor Reading time: 76 min read

Ivosidenib is an orally available small-molecule inhibitor of isocitrate dehydrogenase 2 which is used as an antineoplastic agent in the treatment of selected cases of acute myeloid leukemia (AML). Ivosidenib is associated with a moderate rate of serum aminotransferase elevations during therapy and is suspected to be the cause of rare instances of clinically apparent acute liver injury.

Ivosidenib is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.

Ivosidenib is a tertiary carboxamide resulting from the formal condensation of the carboxy group of (2S)-1-(4-cyanopyridin-2-yl)-5-oxopyrrolidine-2-carboxylic acid with the secondary amino group of (2S)-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-2-[(5-fluoropyridin-3-yl)amino]acetamide. It is approved by the FDA for the treatment of acute myeloid leukemia (AML) in patients with an isocitrate dehydrogenase-1 (IDH1) mutation. It has a role as an antineoplastic agent and an EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor. It is a member of monochlorobenzenes, a cyanopyridine, a member of pyrrolidin-2-ones, an organofluorine compound, a tertiary carboxamide, and a secondary carboxamide.

Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma.[rx] It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. Ivosidenib is an isocitrate dehydrogenase-1 inhibitor that works by decreasing abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG), leading to the differentiation of malignant cells.[rx]

Ivosidenib was approved for medical use in the United States in July 2018. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[rx]

Mechanism of Action

Ivosidenib is a reversible inhibitor of IDH1 which is non-competitive with respect to the cofactor NADH. It binds to many different 132-substituted IDH1 mutants as well as the wild-type enzyme. It is considered to be a slow-binder of the wild-type enzyme and binds to mutant enzymes at lower concentrations, both of which may contribute to its selectivity. Ivosidenib has not been observed to inhibit any form of IDH2 at micromolar concentrations.

Many cancers undergo missense mutations of their IDH1 gene leading to the substitution of arginine 132 residues of the IDH1 enzyme [A35629. This substitution leads to reduced production of the normal carboxylic acid cycle metabolite α-ketoglutarate (α-KG) in favor of a new metabolite, D-2-hydroxyglutarate (D-2HG) which reaches levels of 50-100 fold that of wild type cells. D-2HG is a weak competitor to α-KG, inhibiting aKG-dependent dioxygenases, and is present. These dioxygenases include several histone demethylases. This leads to hypermethylation of histones, a dominant feature of AML, which is associated with less expression of cell-differentiation genes. Furthermore, methylation-sensitive insulators can no longer regulate the activation of oncogenes when histones are hypermethylated. In AML this hypermethylation is known to disrupt hematopoietic differentiation. Ivosidenib reduces the production of D-2HG, relieving the inhibition of histone demethylases and restoring normal methylation conditions. This restores cell differentiation and oncogene regulation leading to the regression of cancer.

Indications

  • Ivosidenib is an orally available small-molecule inhibitor of isocitrate dehydrogenase 2 which is used as an antineoplastic agent in the treatment of selected cases of acute myeloid leukemia (AML).
  • Ivosidenib is approved for use in the treatment of relapsed or refractory AML with a susceptible IDH1 mutation as detected by an FDA-approved test.
  • Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumors, hematopoietic and lymphoid tissue neoplasms), Treatment of malignant neoplasms of the central nervous system
  • Treatment of acute myeloid leukemia. Locally Advanced or Metastatic Cholangiocarcinoma in adults who have been previously treated.
  • Ivosidenib is indicated for people with acute myeloid leukemia and locally advanced or metastatic cholangiocarcinoma.
  • Ivosidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML) in combination azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.[rx] Relapsed or refractory AML in adults.[rx]
  • Acute Myeloid Leukemia
  • Locally Advanced Cholangiocarcinoma
  • Metastatic Cholangiocarcinoma
  • Refractory Acute Myeloid Leukemia (AML)
  • Relapsed Acute Myelogenous Leukemia (AML)

Use in Cancer

Ivosidenib is approved to treat adults whose cancer has a certain mutation in the IDH1 gene, including:

  • Acute myeloid leukemia (AML). It is used:
    • Alone or with azacitidine in patients with newly-diagnosed cancer who are aged 75 years and older or who, due to health problems, cannot receive intensive induction chemotherapy.
    • When cancer has come back or has not gotten better after previous treatment.
  • Cholangiocarcinoma (bile duct cancer) has spread. It is used in adults whose cancer has been treated.

Ivosidenib is also being studied in the treatment of other types of cancer.

Contraindications

  • low amount of magnesium in the blood
  • low amount of calcium in the blood
  • low amount of potassium in the blood
  • Guillain-Barre syndrome
  • torsades de pointes, a type of abnormal heart rhythm
  • prolonged QT interval on EKG
  • chronic heart failure
  • abnormal EKG with QT changes from birth
  • pregnancy
  • a patient who is producing milk and breastfeeding

Dosage

Strengths: 250 mg

Acute Myeloid Leukemia

  • 500 mg orally once daily until disease progression or unacceptable toxicity; for patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response. Select patients for the treatment of AML based on the presence of IDH1 mutations in the blood or bone marrow. Patients without IDH1 mutations at diagnosis should be retested at relapse because a mutation in IDH1 may emerge during therapy and at relapse.
  • For the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Acute Myeloid Leukemia

75 years or older:

  • 500 mg orally once daily until disease progression or unacceptable toxicity; for patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response.
  • For the treatment of adult patients with newly-diagnosed AML with a susceptible IDH1 mutation as detected by an FDA-approved test who are 75 years older or who have comorbidities that preclude the use of intensive induction chemotherapy.

Renal Dose Adjustments

  • Mild (CrCl 60 to less than 90 mL/min) or moderate (CrCl 30 to less than 60 mL/min): No adjustment is recommended.
  • Severe renal impairment (CrCl less than 30 mL/min): Data not available

Liver Dose Adjustments

  • Mild hepatic impairment (total bilirubin less than or equal to the upper limit of normal [ULN] and aspartate aminotransferase [AST] greater than ULN or total bilirubin 1 to 1.5 x ULN and any AST): No adjustment recommended.
  • Moderate hepatic impairment (total bilirubin 1.5 to 3.0 x ULN and any value for AST), or severe hepatic impairment (total bilirubin greater than 3 x ULN and any value for AST): Data not available

Dose Adjustments

DIFFERENTIATION SYNDROME:

  • If differentiation syndrome is suspected, administer systemic corticosteroids and initiate hemodynamic monitoring until symptom resolution and for a minimum of 3 days.
  • Interrupt therapy if severe signs and/or symptoms persist for more than 48 hours after initiation of systemic corticosteroids. Resume therapy when signs and symptoms improve to Grade 2 or less.

NONINFECTIOUS LEUKOCYTOSIS (white blood cell [WBC] count greater than 25 x 10(9)/L or an absolute increase in total WBC of greater than 15 x 10(9)/L from baseline):

  • Initiate treatment with hydroxyurea, as per standard institutional practices, and leukapheresis if clinically indicated.
  • Taper hydroxyurea only after leukocytosis improves or resolves.
  • Interrupt therapy if leukocytosis is not improved with hydroxyurea, and then resume therapy at 500 mg daily when leukocytosis has resolved.

QTC INTERVAL GREATER THAN 480 MSEC TO 500 MSEC:

  • Monitor and supplement electrolyte levels as clinically indicated.
  • Review and adjust concomitant medications with known QTc interval-prolonging effects.
  • Interrupt therapy.
  • Restart therapy at 500 mg once daily after the QTc interval returns to less or equal to 480 msec.
  • Monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation.

QTC INTERVAL GREATER THAN 500 MSEC:

  • Monitor and supplement electrolyte levels as clinically indicated.
  • Review and adjust concomitant medications with known QTc interval-prolonging effects.
  • Interrupt therapy.
  • Resume therapy at a reduced dose of 250 mg once daily when the QTc interval returns to within 30 msec of baseline or less than or equal to 480 msec.
  • Monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation.
  • Consider re-escalating the dose to 500 mg daily if an alternative etiology for QTc prolongation can be identified.

QTC INTERVAL PROLONGATION WITH SIGNS/SYMPTOMS OF LIFE-THREATENING ARRHYTHMIA:

  • Discontinue therapy permanently.

GUILLAIN-BARRE SYNDROME:

  • Discontinue therapy permanently.

OTHER GRADE 3 OR HIGHER TOXICITY CONSIDERED TO BE RELATED TO TREATMENT:

  • Interrupt therapy until toxicity resolves to Grade 2 or lower.
  • Resume therapy at 250 mg once daily; may increase to 500 mg once daily if toxicities resolve to Grade 1 or lower.
  • If Grade 3 or higher toxicity recurs, discontinue therapy.

DOSE MODIFICATION FOR USE WITH STRONG CYP450 3A4 INHIBITORS

  • If a strong CYP450 3A4 inhibitor must be coadministered, reduce the dose of this drug to 250 mg once daily.
  • If the strong CYP450 3A4 inhibitor is discontinued, increase the dose of this drug (after at least 5 half-lives of the strong CYP450 3A4 inhibitor) to the recommended dose of 500 mg once daily.

Administration advice:

  • This drug may be taken with or without food; however, it should not be administered with a high-fat meal because of an increase in drug concentration.
  • Do not split or crush tablets.
  • Administer this drug at about the same time each day.
  • If a dose is vomited, do not administer a replacement dose; wait until the next scheduled dose is due.
  • If a dose is missed or not taken at the usual time, administer the dose as soon as possible and at least 12 hours prior to the next scheduled dose. Return to the normal schedule the following day. Do not administer 2 doses within 12 hours.
  • Assess blood counts and blood chemistries prior to the initiation of therapy, at least once weekly for the first month, once every other week for the second month, and once monthly for the duration of therapy.
  • Monitor blood creatine phosphokinase weekly for the first month of therapy.
  • Monitor electrocardiograms (ECGs) at least once weekly for the first 3 weeks of therapy and then at least once monthly for the duration of therapy. Manage any abnormalities promptly.

Side Effects

The Most Common

  • headache
  • fatigue
  • joint or muscle pain
  • diarrhea
  • constipation
  • vomiting
  • nausea
  • decreased appetite
  • mouth pain and ulcers
  • stomach pain
  • difficulty falling asleep or staying asleep
  • dizziness, lightheadedness, or fainting
  • weakness or tingling sensation in legs, arms, or upper body; numbness and pain on one side or both sides of the body; changes in your ability to see, touch, hear, or taste; burning or prickling sensation; or difficulty breathing
  • chest pain

More common

  • Black, tarry stools
  • bleeding gums
  • blood in the urine or stools
  • blurred vision
  • burning, tingling, numbness or pain in the hands, arms, feet, or legs
  • chest pain or tightness
  • chills
  • confusion
  • cough
  • decreased urination
  • difficult or labored breathing
  • difficulty in moving
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • eye pain
  • fainting
  • fever
  • general feeling of illness
  • headache
  • irregular heartbeat, recurrent
  • joint pain, stiffness, or swelling
  • lower back, side, or stomach pain
  • muscle ache, cramps, pain, or stiffness
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • rapid weight gain
  • rash
  • the sensation of pins and needles
  • sore throat
  • sores, ulcers, or white spots on the lips, tongue, or inside the mouth
  • stabbing pain
  • swelling of your arms, feet, or lower legs
  • unusual bleeding or bruising
  • unusual tiredness or weakness

Rare

  • Inability to move the arms and legs
  • sudden numbness and weakness in the arms and legs
  • Cracked lips
  • decreased appetite
  • diarrhea
  • difficulty in swallowing
  • nausea
  • vomiting
  • decreased urination;
  • rapid weight gain; or
  • swelling in your arms or legs.
  • fast or pounding heartbeats, fluttering in your chest, shortness of breath, sudden dizziness (like you might pass out);
  • jaundice (yellowing of the skin or eyes);
  • fluid build-up around the stomach–rapid weight gain, stomach pain and bloating, trouble breathing while lying down;
  • low red blood cells (anemia)–pale skin, tiredness, feeling light-headed or short of breath, cold hands and feet;
  • high white blood cell counts–fever, weakness, not feeling well, bleeding or bruising, nausea, loss of appetite, weight loss; or
  • nervous system problems–numbness, pain, tingling, weakness, burning or prickly feeling, vision or hearing problems, trouble breathing.

Drug Interactions

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

Based on animal embryo-fetal toxicity studies, TIBSOVO may cause fetal harm when administered to a pregnant woman. There are no available data on TIBSOVO use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. In animal
embryo-fetal toxicity studies, oral administration of ivosidenib to pregnant rats and rabbits during organogenesis was associated with embryo-fetal mortality and alterations to growth starting at 2 times the steady-state clinical exposure based on the AUC at the recommended
human dose (see Data). If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, advise the patient of the potential risk to a fetus.

Lactation

There are no data on the presence of ivosidenib or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Because many drugs are excreted in human milk and because of the potential for adverse reactions in breastfed children, advise women not to breastfeed during treatment with TIBSOVO and for at least 1 month after the last dose.

Why is this medication prescribed?

Ivosidenib is used to treat a certain type of acute myeloid leukemia (AML; a type of cancer that begins in the white blood cells) that has returned or that has not improved after previous treatment(s). Ivosidenib is also used alone or in combination with azacitidine (Onureg) to treat a certain type of AML in some adults older than 75 years of age as a first treatment. Ivosidenib is also used in adults who have already received previous treatment(s) to treat a certain type of cholangiocarcinoma (bile duct cancer) that has spread to nearby tissues or other parts of the body. Ivosidenib is in a class of medications called IDH1 inhibitors. It works by slowing or stopping the growth of cancer cells.

How should this medicine be used?

Ivosidenib comes as a tablet to take by mouth. It is usually taken with or without food once daily. Do not take it with high-fat food such as eggs, butter, whole-milk dairy products (such as whole milk, cheese, and yogurt), fried foods, or fast food. Take ivosidenib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take ivosidenib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the tablets whole; do not split, chew, or crush them. If you vomit after taking ivosidenib, do not take another dose. Continue your regular dosing schedule.

Your doctor may reduce your dose or temporarily or permanently stop your treatment with ivosidenib depending on your response to treatment or any side effects that you experience. Talk to your doctor about how you are feeling during your treatment. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before taking ivosidenib,

  • tell your doctor and pharmacist if you are allergic to ivosidenib, any other medications, or any of the ingredients in ivosidenib tablets. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor if you or anyone in your family has or has ever had a prolonged QT interval (a condition that increases the risk of developing an irregular heartbeat that may cause fainting or sudden death); if you have or have ever had a slow or irregular heartbeat, heart failure, or other heart problems; low blood levels of sodium, potassium, calcium, or magnesium; nervous system problems; liver disease, including cirrhosis; or if you are receiving dialysis treatments or if you have or ever had kidney disease.
  • tell your doctor if you are pregnant or plan to become pregnant, or are breastfeeding. You should know that ivosidenib may decrease the effectiveness of hormonal contraceptives (birth control pills, patches, rings, or injections) while you are taking this medication. Talk to your doctor about using another form of birth control. If you become pregnant while taking ivosidenib, call your doctor immediately. Ivosidenib may cause fetal harm.
  • tell your doctor if are breastfeeding. Do not breastfeed during your treatment with ivosidenib and for 1 month after your final dose.

What special dietary instructions should I follow?

Unless your doctor tells you otherwise, continue your normal diet. Make sure you drink plenty of water or other fluids every day while you are taking ivosidenib.

What should I do if I forget a dose?

If your next dose is due in 12 hours or more, take the missed dose as soon as you remember it. However, if the next dose will be taken in less than 12 hours, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

References

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf
  4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf
  5. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/211192Orig1s009ltr.pdf
  6. https://pubchem.ncbi.nlm.nih.gov/compound/71657455
  7. https://go.drugbank.com/drugs/DB14568
  8. https://en.wikipedia.org/wiki/Ivosidenib
  9. https://www.drugs.com/mtm/ivosidenib.html
  10. https://medlineplus.gov/druginfo/meds/a618042.html
  11. https://www.cancer.gov/about-cancer/treatment/drugs/ivosidenib
  12. https://www.mayoclinic.org/drugs-supplements/ivosidenib-oral-route/side-effects/drg-20443890?p=1
  13. https://www.webmd.com/drugs/2/drug-175695/ivosidenib-oral/details/list-contraindications
  14. CAS Common Chemistry
    https://creativecommons.org/licenses/by-nc/4.0/
    https://commonchemistry.cas.org/detail?cas_rn=1448347-49-6
  15. ChemIDplus
    https://www.nlm.nih.gov/copyright.html
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=1448347496
    https://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus
  16. DrugBank
    https://www.drugbank.ca/legal/terms_of_use
    https://www.drugbank.ca/drugs/DB14568
  17. EPA DSSTox
    https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
    https://comptox.epa.gov/dashboard/DTXSID801027928
    https://comptox.epa.gov/dashboard/chemical-lists/
  18. European Chemicals Agency (ECHA)
    https://echa.europa.eu/web/guest/legal-notice
    https://echa.europa.eu/information-on-chemicals
    https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/249162
  19. FDA Global Substance Registration System (GSRS)
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://gsrs.ncats.nih.gov/ginas/app/beta/substances/Q2PCN8MAM6
  20. ChEBI
    http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:145430
    http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
  21. LiverTox
    https://www.nlm.nih.gov/copyright.html
    https://www.ncbi.nlm.nih.gov/books/n/livertox/Ivosidenib/
  22. NCI Thesaurus (NCIt)
    https://www.cancer.gov/policies/copyright-reuse
    https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C114383
    https://ncit.nci.nih.gov
  23. ChEMBL
    http://www.ebi.ac.uk/Information/termsofuse.html
    https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3989958/
    https://www.ebi.ac.uk/chembl/g/#browse/targets
  24. Drug Gene Interaction database (DGIdb)
    http://www.dgidb.org/downloads
    https://www.dgidb.org/drugs/IVOSIDENIB
  25. IUPHAR/BPS Guide to PHARMACOLOGY
    https://www.guidetopharmacology.org/about.jsp#license
    https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9217
    https://www.guidetopharmacology.org/targets.jsp
  26. Therapeutic Target Database (TTD)
    http://idrblab.net/ttd/data/drug/details/D07DCG
  27. ClinicalTrials.gov
    https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
    https://clinicaltrials.gov/
  28. DailyMed
    https://www.nlm.nih.gov/copyright.html
    https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=IVOSIDENIB
  29. European Medicines Agency (EMA)
    https://www.ema.europa.eu/en/about-us/legal-notice
    https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002247-pip02-17
    https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002247-pip03-17
  30. EU Clinical Trials Register
    https://www.clinicaltrialsregister.eu/
  31. FDA Orange Book
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  32. FDA Medication Guides
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=medguide.page
  33. National Drug Code (NDC) Directory
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
  34. NCI Cancer Drugs
    https://www.cancer.gov/policies/copyright-reuse
    https://www.cancer.gov/about-cancer/treatment/drugs/ivosidenib
  35. NLM RxNorm Terminology
    https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
    https://rxnav.nlm.nih.gov/id/rxnorm/2049873
  36. Springer Nature
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=41061193-220086950
  37. Thieme Chemistry
    https://creativecommons.org/licenses/by-nc-nd/4.0/
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=41061193-220081096
  38. WHO Anatomical Therapeutic Chemical (ATC) Classification
    https://www.whocc.no/copyright_disclaimer/
    https://www.whocc.no/atc/
    https://www.whocc.no/atc_ddd_index/
  39. Wikidata
    https://creativecommons.org/publicdomain/zero/1.0/
    https://www.wikidata.org/wiki/Q27895417
  40. https://pubchem.ncbi.nlm.nih.gov
    https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false
  41. Medical Subject Headings (MeSH)
    https://www.nlm.nih.gov/copyright.html
    https://www.ncbi.nlm.nih.gov/mesh/2026879
    http://www.nlm.nih.gov/mesh/meshhome.html
    https://www.ncbi.nlm.nih.gov/mesh/68000970
    https://www.ncbi.nlm.nih.gov/mesh/68004791
  42. KEGG
    https://www.kegg.jp/kegg/legal.html
    http://www.genome.jp/kegg-bin/get_htext?br08302.keg
    http://www.genome.jp/kegg-bin/get_htext?br08303.keg
    http://www.genome.jp/kegg-bin/get_htext?br08310.keg
  43. UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
    http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
  44. PATENTSCOPE (WIPO)
    https://pubchem.ncbi.nlm.nih.gov/substance/393443997

Frequently Asked Questions

Mechanism of ActionIvosidenib is a reversible inhibitor of IDH1 which is non-competitive with respect to the cofactor NADH. It binds to many different 132-substituted IDH1 mutants as well as the wild-type enzyme. It is considered to be a slow-binder of the wild-type enzyme and binds to mutant enzymes at lower concentrations, both of which may contribute to its selectivity. Ivosidenib has not been observed to inhibit any form of IDH2 at micromolar concentrations.Many cancers undergo missense mutations of their IDH1 gene leading to the substitution of arginine 132 residues of the IDH1 enzyme [A35629. This substitution leads to reduced production of the normal carboxylic acid cycle metabolite α-ketoglutarate (α-KG) in favor of a new metabolite, D-2-hydroxyglutarate (D-2HG) which reaches levels of 50-100 fold that of wild type cells. D-2HG is a weak competitor to α-KG, inhibiting aKG-dependent dioxygenases, and is present. These dioxygenases include several histone demethylases. This leads to hypermethylation of histones, a dominant feature of AML, which is associated with less expression of cell-differentiation genes. Furthermore, methylation-sensitive insulators can no longer regulate the activation of oncogenes when histones are hypermethylated. In AML this hypermethylation is known to disrupt hematopoietic differentiation. Ivosidenib reduces the production of D-2HG, relieving the inhibition of histone demethylases and restoring normal methylation conditions. This restores cell differentiation and oncogene regulation leading to the regression of cancer.IndicationsIvosidenib is an orally available small-molecule inhibitor of isocitrate dehydrogenase 2 which is used as an antineoplastic agent in the treatment of selected cases of acute myeloid leukemia (AML). Ivosidenib is approved for use in the treatment of relapsed or refractory AML with a susceptible IDH1 mutation as detected by an FDA-approved test. Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumors, hematopoietic and lymphoid tissue neoplasms), Treatment of malignant neoplasms of the central nervous system Treatment of acute myeloid leukemia. Locally Advanced or Metastatic Cholangiocarcinoma in adults who have been previously treated. Ivosidenib is indicated for people with acute myeloid leukemia and locally advanced or metastatic cholangiocarcinoma. Ivosidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML) in combination azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.[rx] Relapsed or refractory AML in adults.[rx] Acute Myeloid Leukemia Locally Advanced Cholangiocarcinoma Metastatic Cholangiocarcinoma Refractory Acute Myeloid Leukemia (AML) Relapsed Acute Myelogenous Leukemia (AML)Use in Cancer Ivosidenib is approved to treat adults whose cancer has a certain mutation in the IDH1 gene, including:Acute myeloid leukemia (AML). It is used:Alone or with azacitidine in patients with newly-diagnosed cancer who are aged 75 years and older or who, due to health problems, cannot receive intensive induction chemotherapy. When cancer has come back or has not gotten better after previous treatment.Cholangiocarcinoma (bile duct cancer) has spread. It is used in adults whose cancer has been treated.Ivosidenib is also being studied in the treatment of other types of cancer.Contraindicationslow amount of magnesium in the blood low amount of calcium in the blood low amount of potassium in the blood Guillain-Barre syndrome torsades de pointes, a type of abnormal heart rhythm prolonged QT interval on EKG chronic heart failure abnormal EKG with QT changes from birth pregnancy a patient who is producing milk and breastfeedingDosage Strengths: 250 mg Acute Myeloid Leukemia500 mg orally once daily until disease progression or unacceptable toxicity; for patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response. Select patients for the treatment of AML based on the presence of IDH1 mutations in the blood or bone marrow. Patients without IDH1 mutations at diagnosis should be retested at relapse because a mutation in IDH1 may emerge during therapy and at relapse. For the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.Acute Myeloid Leukemia 75 years or older:500 mg orally once daily until disease progression or unacceptable toxicity; for patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response. For the treatment of adult patients with newly-diagnosed AML with a susceptible IDH1 mutation as detected by an FDA-approved test who are 75 years older or who have comorbidities that preclude the use of intensive induction chemotherapy.Renal Dose AdjustmentsMild (CrCl 60 to less than 90 mL/min) or moderate (CrCl 30 to less than 60 mL/min): No adjustment is recommended. Severe renal impairment (CrCl less than 30 mL/min): Data not availableLiver Dose AdjustmentsMild hepatic impairment (total bilirubin less than or equal to the upper limit of normal [ULN] and aspartate aminotransferase [AST] greater than ULN or total bilirubin 1 to 1.5 x ULN and any AST): No adjustment recommended. Moderate hepatic impairment (total bilirubin 1.5 to 3.0 x ULN and any value for AST), or severe hepatic impairment (total bilirubin greater than 3 x ULN and any value for AST): Data not availableDose Adjustments DIFFERENTIATION SYNDROME:If differentiation syndrome is suspected, administer systemic corticosteroids and initiate hemodynamic monitoring until symptom resolution and for a minimum of 3 days. Interrupt therapy if severe signs and/or symptoms persist for more than 48 hours after initiation of systemic corticosteroids. Resume therapy when signs and symptoms improve to Grade 2 or less.NONINFECTIOUS LEUKOCYTOSIS (white blood cell [WBC] count greater than 25 x 10(9)/L or an absolute increase in total WBC of greater than 15 x 10(9)/L from baseline):Initiate treatment with hydroxyurea, as per standard institutional practices, and leukapheresis if clinically indicated. Taper hydroxyurea only after leukocytosis improves or resolves. Interrupt therapy if leukocytosis is not improved with hydroxyurea, and then resume therapy at 500 mg daily when leukocytosis has resolved.QTC INTERVAL GREATER THAN 480 MSEC TO 500 MSEC:Monitor and supplement electrolyte levels as clinically indicated. Review and adjust concomitant medications with known QTc interval-prolonging effects. Interrupt therapy. Restart therapy at 500 mg once daily after the QTc interval returns to less or equal to 480 msec. Monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation.QTC INTERVAL GREATER THAN 500 MSEC:Monitor and supplement electrolyte levels as clinically indicated. Review and adjust concomitant medications with known QTc interval-prolonging effects. Interrupt therapy. Resume therapy at a reduced dose of 250 mg once daily when the QTc interval returns to within 30 msec of baseline or less than or equal to 480 msec. Monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation. Consider re-escalating the dose to 500 mg daily if an alternative etiology for QTc prolongation can be identified.QTC INTERVAL PROLONGATION WITH SIGNS/SYMPTOMS OF LIFE-THREATENING ARRHYTHMIA:Discontinue therapy permanently.GUILLAIN-BARRE SYNDROME:Discontinue therapy permanently.OTHER GRADE 3 OR HIGHER TOXICITY CONSIDERED TO BE RELATED TO TREATMENT:Interrupt therapy until toxicity resolves to Grade 2 or lower. Resume therapy at 250 mg once daily; may increase to 500 mg once daily if toxicities resolve to Grade 1 or lower. If Grade 3 or higher toxicity recurs, discontinue therapy.DOSE MODIFICATION FOR USE WITH STRONG CYP450 3A4 INHIBITORSIf a strong CYP450 3A4 inhibitor must be coadministered, reduce the dose of this drug to 250 mg once daily. If the strong CYP450 3A4 inhibitor is discontinued, increase the dose of this drug (after at least 5 half-lives of the strong CYP450 3A4 inhibitor) to the recommended dose of 500 mg once daily.Administration advice:This drug may be taken with or without food; however, it should not be administered with a high-fat meal because of an increase in drug concentration. Do not split or crush tablets. Administer this drug at about the same time each day. If a dose is vomited, do not administer a replacement dose; wait until the next scheduled dose is due. If a dose is missed or not taken at the usual time, administer the dose as soon as possible and at least 12 hours prior to the next scheduled dose. Return to the normal schedule the following day. Do not administer 2 doses within 12 hours. Assess blood counts and blood chemistries prior to the initiation of therapy, at least once weekly for the first month, once every other week for the second month, and once monthly for the duration of therapy. Monitor blood creatine phosphokinase weekly for the first month of therapy. Monitor electrocardiograms (ECGs) at least once weekly for the first 3 weeks of therapy and then at least once monthly for the duration of therapy. Manage any abnormalities promptly.Side Effects The Most Commonheadache fatigue joint or muscle pain diarrhea constipation vomiting nausea decreased appetite mouth pain and ulcers stomach pain difficulty falling asleep or staying asleep dizziness, lightheadedness, or fainting weakness or tingling sensation in legs, arms, or upper body; numbness and pain on one side or both sides of the body; changes in your ability to see, touch, hear, or taste; burning or prickling sensation; or difficulty breathing chest painMore commonBlack, tarry stools bleeding gums blood in the urine or stools blurred vision burning, tingling, numbness or pain in the hands, arms, feet, or legs chest pain or tightness chills confusion cough decreased urination difficult or labored breathing difficulty in moving dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position eye pain fainting fever general feeling of illness headache irregular heartbeat, recurrent joint pain, stiffness, or swelling lower back, side, or stomach pain muscle ache, cramps, pain, or stiffness painful or difficult urination pale skin pinpoint red spots on the skin rapid weight gain rash the sensation of pins and needles sore throat sores, ulcers, or white spots on the lips, tongue, or inside the mouth stabbing pain swelling of your arms, feet, or lower legs unusual bleeding or bruising unusual tiredness or weaknessRareInability to move the arms and legs sudden numbness and weakness in the arms and legs Cracked lips decreased appetite diarrhea difficulty in swallowing nausea vomiting decreased urination; rapid weight gain; or swelling in your arms or legs. fast or pounding heartbeats, fluttering in your chest, shortness of breath, sudden dizziness (like you might pass out); jaundice (yellowing of the skin or eyes); fluid build-up around the stomach--rapid weight gain, stomach pain and bloating, trouble breathing while lying down; low red blood cells (anemia)--pale skin, tiredness, feeling light-headed or short of breath, cold hands and feet; high white blood cell counts--fever, weakness, not feeling well, bleeding or bruising, nausea, loss of appetite, weight loss; or nervous system problems--numbness, pain, tingling, weakness, burning or prickly feeling, vision or hearing problems, trouble breathing.Drug InteractionsDRUG INTERACTION1,2-Benzodiazepine The metabolism of 1,2-Benzodiazepine can be increased when combined with Ivosidenib.Abametapir The serum concentration of Ivosidenib can be increased when it is combined with Abametapir.Abatacept The metabolism of Ivosidenib can be increased when combined with Abatacept.Abemaciclib The metabolism of Abemaciclib can be increased when combined with Ivosidenib.Abiraterone The metabolism of Abiraterone can be increased when combined with Ivosidenib.Abrocitinib The metabolism of Abrocitinib can be increased when combined with Ivosidenib.Acalabrutinib The metabolism of Acalabrutinib can be increased when combined with Ivosidenib.Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Ivosidenib.Acetaminophen The metabolism of Acetaminophen can be increased when combined with Ivosidenib.Acetazolamide The metabolism of Ivosidenib can be decreased when combined with Acetazolamide.Acetohexamide The metabolism of Acetohexamide can be increased when combined with Ivosidenib.Acetylsalicylic acid The metabolism of Acetylsalicylic acid can be increased when combined with Ivosidenib.Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Ivosidenib.Adalimumab The metabolism of Ivosidenib can be increased when combined with Adalimumab.Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Ivosidenib.Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Ivosidenib.Albendazole The metabolism of Albendazole can be increased when combined with Ivosidenib.Alclometasone The metabolism of Alclometasone can be increased when combined with Ivosidenib.Aldesleukin The metabolism of Ivosidenib can be decreased when combined with Aldesleukin.Alectinib The metabolism of Alectinib can be increased when combined with Ivosidenib.Alfentanil The metabolism of Alfentanil can be increased when combined with Ivosidenib.Alfuzosin The metabolism of Alfuzosin can be increased when combined with Ivosidenib.Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Ivosidenib.Aliskiren The metabolism of Aliskiren can be increased when combined with Ivosidenib.Almotriptan The metabolism of Almotriptan can be increased when combined with Ivosidenib.Alogliptin The metabolism of Alogliptin can be increased when combined with Ivosidenib.Alosetron The metabolism of Alosetron can be increased when combined with Ivosidenib.Alpelisib The metabolism of Alpelisib can be increased when combined with Ivosidenib.Alprazolam The metabolism of Alprazolam can be increased when combined with Ivosidenib.Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Ivosidenib.Ambrisentan The metabolism of Ambrisentan can be increased when combined with Ivosidenib.Ambroxol The metabolism of Ambroxol can be increased when combined with Ivosidenib.Amcinonide The metabolism of Amcinonide can be increased when combined with Ivosidenib.Amifampridine The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Ivosidenib.Aminoglutethimide The metabolism of Ivosidenib can be increased when combined with Aminoglutethimide.Aminophenazone The metabolism of Aminophenazone can be increased when combined with Ivosidenib.Aminophylline The metabolism of Aminophylline can be increased when combined with Ivosidenib.Amiodarone The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Ivosidenib.Amisulpride The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Amisulpride.Amitriptyline The metabolism of Amitriptyline can be increased when combined with Ivosidenib.Amlodipine The metabolism of Amlodipine can be increased when combined with Ivosidenib.Amobarbital The metabolism of Ivosidenib can be increased when combined with Amobarbital.Amodiaquine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Ivosidenib.Amoxapine The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Ivosidenib.Amprenavir The metabolism of Ivosidenib can be decreased when combined with Amprenavir.Anagrelide The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Ivosidenib.Anakinra The metabolism of Ivosidenib can be increased when combined with Anakinra.Antazoline The risk or severity of QTc prolongation can be increased when Antazoline is combined with Ivosidenib.Antipyrine The metabolism of Antipyrine can be increased when combined with Ivosidenib.Apalutamide The metabolism of Ivosidenib can be increased when combined with Apalutamide.Apixaban The metabolism of Apixaban can be increased when combined with Ivosidenib.Apomorphine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Ivosidenib.Apremilast The metabolism of Apremilast can be increased when combined with Ivosidenib.Aprepitant The metabolism of Ivosidenib can be decreased when combined with Aprepitant.Arformoterol The metabolism of Arformoterol can be increased when combined with Ivosidenib.Aripiprazole The metabolism of Aripiprazole can be increased when combined with Ivosidenib.Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Ivosidenib.Armodafinil The metabolism of Ivosidenib can be increased when combined with Armodafinil.Arsenic trioxide The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Ivosidenib.Artemether The risk or severity of QTc prolongation can be increased when Artemether is combined with Ivosidenib.Articaine The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Articaine.Asciminib The serum concentration of Ivosidenib can be increased when it is combined with Asciminib.Asenapine The risk or severity of QTc prolongation can be increased when Asenapine is combined with Ivosidenib.Astemizole The risk or severity of QTc prolongation can be increased when Astemizole is combined with Ivosidenib.Asunaprevir The metabolism of Asunaprevir can be increased when combined with Ivosidenib.Atazanavir The metabolism of Ivosidenib can be decreased when combined with Atazanavir.Atogepant The metabolism of Atogepant can be increased when combined with Ivosidenib.Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ivosidenib.Atorvastatin The metabolism of Atorvastatin can be increased when combined with Ivosidenib.Atovaquone The metabolism of Atovaquone can be increased when combined with Ivosidenib.Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with Ivosidenib.Avacopan The metabolism of Avacopan can be increased when combined with Ivosidenib.Avanafil The metabolism of Avanafil can be increased when combined with Ivosidenib.Avapritinib The metabolism of Avapritinib can be increased when combined with Ivosidenib.Axitinib The metabolism of Axitinib can be increased when combined with Ivosidenib.Azatadine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Ivosidenib.Azelastine The metabolism of Azelastine can be increased when combined with Ivosidenib.Azithromycin The metabolism of Azithromycin can be increased when combined with Ivosidenib.Baricitinib The metabolism of Baricitinib can be increased when combined with Ivosidenib.Beclomethasone The metabolism of Beclomethasone dipropionate can be increased when combined with Ivosidenib.Bedaquiline The metabolism of Bedaquiline can be increased when combined with Ivosidenib.Belumosudil The metabolism of Belumosudil can be increased when combined with Ivosidenib.Belzutifan The serum concentration of Ivosidenib can be decreased when it is combined with Belzutifan.Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Ivosidenib.Benzocaine The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Benzocaine.Benzphetamine The metabolism of Benzphetamine can be increased when combined with Ivosidenib.Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Benzyl alcohol.Bepridil The risk or severity of QTc prolongation can be increased when Bepridil is combined with Ivosidenib.Berotralstat The serum concentration of Ivosidenib can be increased when it is combined with Berotralstat.Betamethasone The metabolism of Betamethasone can be increased when combined with Ivosidenib.Betamethasone The metabolism of Betamethasone phosphate can be increased when combined with Ivosidenib.Bexarotene The metabolism of Bexarotene can be increased when combined with Ivosidenib.Bezafibrate The metabolism of Bezafibrate can be increased when combined with Ivosidenib.Bicalutamide The metabolism of Bicalutamide can be increased when combined with Ivosidenib.Bictegravir The metabolism of Bictegravir can be increased when combined with Ivosidenib.Bifonazole The metabolism of Ivosidenib can be decreased when combined with Bifonazole.Bilastine The risk or severity of QTc prolongation can be increased when Bilastine is combined with Ivosidenib.Bimekizumab The metabolism of Ivosidenib can be increased when combined with Bimekizumab.Bioallethrin The metabolism of Bioallethrin can be increased when combined with Ivosidenib.Bisoprolol The metabolism of Bisoprolol can be increased when combined with Ivosidenib.Boceprevir The metabolism of Ivosidenib can be decreased when combined with Boceprevir.Bortezomib The metabolism of Bortezomib can be increased when combined with Ivosidenib.Bosentan The metabolism of Bosentan can be increased when combined with Ivosidenib.Bosutinib The metabolism of Bosutinib can be increased when combined with Ivosidenib.Brentuximab The metabolism of Brentuximab vedotin can be increased when combined with Ivosidenib.Bretylium The risk or severity of QTc prolongation can be increased when Bretylium is combined with Ivosidenib.Brexpiprazole The metabolism of Brexpiprazole can be increased when combined with Ivosidenib.Brigatinib The metabolism of Brigatinib can be increased when combined with Ivosidenib.Brinzolamide The metabolism of Brinzolamide can be increased when combined with Ivosidenib.Brivaracetam The metabolism of Brivaracetam can be increased when combined with Ivosidenib.Bromocriptine The metabolism of Bromocriptine can be increased when combined with Ivosidenib.Brompheniramine The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Ivosidenib.Buclizine The risk or severity of QTc prolongation can be increased when Buclizine is combined with Ivosidenib.Budesonide The metabolism of Budesonide can be increased when combined with Ivosidenib.Bupivacaine The metabolism of Bupivacaine can be increased when combined with Ivosidenib.Buprenorphine The metabolism of Buprenorphine can be increased when combined with Ivosidenib.Bupropion The metabolism of Bupropion can be increased when combined with Ivosidenib.Buserelin The risk or severity of QTc prolongation can be increased when Buserelin is combined with Ivosidenib.Buspirone The metabolism of Buspirone can be increased when combined with Ivosidenib.Busulfan The metabolism of Busulfan can be increased when combined with Ivosidenib.Butacaine The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Butacaine.Butalbital The metabolism of Ivosidenib can be increased when combined with Butalbital.Butamben The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Butamben.Butriptyline The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Ivosidenib.Cabazitaxel The metabolism of Cabazitaxel can be increased when combined with Ivosidenib.Cabergoline The metabolism of Cabergoline can be increased when combined with Ivosidenib.Cabozantinib The metabolism of Cabozantinib can be increased when combined with Ivosidenib.Calcitriol The metabolism of Calcitriol can be increased when combined with Ivosidenib.Canagliflozin The metabolism of Canagliflozin can be increased when combined with Ivosidenib.Canakinumab The metabolism of Ivosidenib can be increased when combined with Canakinumab.Candesartan cilexetil The metabolism of Candesartan cilexetil can be increased when combined with Ivosidenib.Candicidin The metabolism of Ivosidenib can be decreased when combined with Candicidin.Cannabidiol The metabolism of Cannabidiol can be increased when combined with Ivosidenib.Capecitabine The metabolism of Capecitabine can be increased when combined with Ivosidenib.Capmatinib The serum concentration of Capmatinib can be decreased when it is combined with Ivosidenib.Capsaicin The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Capsaicin.Carbamazepine The metabolism of Ivosidenib can be increased when combined with Carbamazepine.Carbinoxamine The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Ivosidenib.Cariprazine The metabolism of Cariprazine can be increased when combined with Ivosidenib.Carvedilol The metabolism of Carvedilol can be increased when combined with Ivosidenib.Cefradine The metabolism of Ivosidenib can be increased when combined with Cefradine.Celecoxib The metabolism of Celecoxib can be increased when combined with Ivosidenib.Celiprolol The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Ivosidenib.Cenobamate The serum concentration of Ivosidenib can be decreased when it is combined with Cenobamate.Cephalexin The metabolism of Cephalexin can be increased when combined with Ivosidenib.Ceritinib The metabolism of Ceritinib can be increased when combined with Ivosidenib.Cerivastatin The metabolism of Cerivastatin can be increased when combined with Ivosidenib.Certolizumab pegol The metabolism of Ivosidenib can be increased when combined with Certolizumab pegol.Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Ivosidenib.Cevimeline The metabolism of Cevimeline can be increased when combined with Ivosidenib.Chenodeoxycholic The metabolism of Chenodeoxycholic acid can be increased when combined with Ivosidenib.Chloramphenicol The metabolism of Ivosidenib can be decreased when combined with Chloramphenicol.Chlorcyclizine The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Ivosidenib.Chloroprocaine The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Chloroprocaine.Chloroquine The metabolism of Chloroquine can be increased when combined with Ivosidenib.Chlorpheniramine The metabolism of Chlorpheniramine can be increased when combined with Ivosidenib.Chlorpromazine The metabolism of Chlorpromazine can be increased when combined with Ivosidenib.Chlorpropamide The metabolism of Chlorpropamide can be increased when combined with Ivosidenib.Chlorprothixene The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Ivosidenib.Chlorzoxazone The metabolism of Chlorzoxazone can be increased when combined with Ivosidenib.Cholecalciferol The metabolism of Cholecalciferol can be increased when combined with Ivosidenib.Ciclesonide The metabolism of Ciclesonide can be increased when combined with Ivosidenib.Cilostazol The metabolism of Cilostazol can be increased when combined with Ivosidenib.Cimetidine The metabolism of Ivosidenib can be decreased when combined with Cimetidine.Cinacalcet The metabolism of Cinacalcet can be increased when combined with Ivosidenib.Cinchocaine The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Cinchocaine.Cinnarizine The metabolism of Cinnarizine can be increased when combined with Ivosidenib.Cinoxacin The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Ivosidenib.Ciprofloxacin The metabolism of Ivosidenib can be decreased when combined with Ciprofloxacin.Cisapride The risk or severity of QTc prolongation can be increased when Cisapride is combined with Ivosidenib.Citalopram The risk or severity of QTc prolongation can be increased when Citalopram is combined with Ivosidenib.Clarithromycin The metabolism of Ivosidenib can be decreased when combined with Clarithromycin.Clemastine The risk or severity of QTc prolongation can be increased when Clemastine is combined with Ivosidenib.Clevidipine The metabolism of Clevidipine can be increased when combined with Ivosidenib.Clindamycin The metabolism of Clindamycin can be increased when combined with Ivosidenib.Clobazam The metabolism of Clobazam can be increased when combined with Ivosidenib.Clobetasol The metabolism of Clobetasol can be increased when combined with Ivosidenib.Clobetasol pro The metabolism of Clobetasol propionate can be increased when combined with Ivosidenib.Clobetasone The metabolism of Clobetasone can be increased when combined with Ivosidenib.Clofazimine The metabolism of Ivosidenib can be decreased when combined with Clofazimine.Clofibrate The metabolism of Clofibrate can be increased when combined with Ivosidenib.Clomipramine The metabolism of Clomipramine can be increased when combined with Ivosidenib.Clonazepam The metabolism of Clonazepam can be increased when combined with Ivosidenib.Clonidine The metabolism of Clonidine can be increased when combined with Ivosidenib.Clopidogrel The metabolism of Clopidogrel can be increased when combined with Ivosidenib.Clorazepic acid The metabolism of Clorazepic acid can be increased when combined with Ivosidenib.Clotiazepam The metabolism of Clotiazepam can be increased when combined with Ivosidenib.Clozapine The metabolism of Ivosidenib can be decreased when combined with Clozapine.Cobicistat The metabolism of Ivosidenib can be decreased when combined with Cobicistat.Cobimetinib The metabolism of Cobimetinib can be increased when combined with Ivosidenib.Cocaine The risk or severity of QTc prolongation can be increased when Cocaine is combined with Ivosidenib.Codeine The metabolism of Codeine can be increased when combined with Ivosidenib.Colchicine The metabolism of Colchicine can be increased when combined with Ivosidenib.Conivaptan The metabolism of Ivosidenib can be decreased when combined with Conivaptan.Conjugated es The metabolism of Conjugated estrogens can be increased when combined with Ivosidenib.Copanlisib The metabolism of Copanlisib can be increased when combined with Ivosidenib.Corticotropin The metabolism of Corticotropin can be increased when combined with Ivosidenib.Cortisone acetate The metabolism of Cortisone acetate can be increased when combined with Ivosidenib.Crizotinib The metabolism of Ivosidenib can be decreased when combined with Crizotinib.Curcumin The metabolism of Ivosidenib can be decreased when combined with Curcumin.Cyclandelate The metabolism of Cyclandelate can be increased when combined with Ivosidenib.Cyclizine The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Ivosidenib.Cyclobenzaprine The metabolism of Cyclobenzaprine can be increased when combined with Ivosidenib.Cyclophosphamide The metabolism of Cyclophosphamide can be increased when combined with Ivosidenib.Cyclosporine The metabolism of Ivosidenib can be decreased when combined with Cyclosporine.Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Ivosidenib.Cyproterone ac The metabolism of Cyproterone acetate can be increased when combined with Ivosidenib.Dabrafenib The metabolism of Dabrafenib can be increased when combined with Ivosidenib.Daclatasvir The metabolism of Daclatasvir can be increased when combined with Ivosidenib.Dacomitinib The metabolism of Dacomitinib can be increased when combined with Ivosidenib.Dalfopristin The metabolism of Ivosidenib can be decreased when combined with Dalfopristin.Danazol The metabolism of Ivosidenib can be decreased when combined with Danazol.Dapagliflozin The metabolism of Dapagliflozin can be increased when combined with Ivosidenib.Dapsone The metabolism of Dapsone can be increased when combined with Ivosidenib.Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ivosidenib.Daridorexant The metabolism of Daridorexant can be increased when combined with Ivosidenib.Darifenacin The metabolism of Darifenacin can be increased when combined with Ivosidenib.Darolutamide The metabolism of Darolutamide can be increased when combined with Ivosidenib.Darunavir The serum concentration of Ivosidenib can be increased when it is combined with Darunavir.Dasabuvir The metabolism of Dasabuvir can be increased when combined with Ivosidenib.Dasatinib The metabolism of Dasatinib can be increased when combined with Ivosidenib.Daunorubicin The metabolism of Ivosidenib can be decreased when combined with Daunorubicin.Deferasirox The metabolism of Ivosidenib can be increased when combined with Deferasirox.Deflazacort The metabolism of Deflazacort can be increased when combined with Ivosidenib.Degarelix The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ivosidenib.Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Ivosidenib.Delamanid The metabolism of Delamanid can be increased when combined with Ivosidenib.Delavirdine The metabolism of Ivosidenib can be decreased when combined with Delavirdine.Desflurane The risk or severity of QTc prolongation can be increased when Desflurane is combined with Ivosidenib.Desipramine The metabolism of Ivosidenib can be decreased when combined with Desipramine.Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Ivosidenib.Desogestrel The metabolism of Desogestrel can be increased when combined with Ivosidenib.Desonide The metabolism of Desonide can be increased when combined with Ivosidenib.Desoxycorticost The metabolism of Desoxycorticosterone acetate can be increased when combined with Ivosidenib.Desvenlafaxine The metabolism of Ivosidenib can be decreased when combined with Desvenlafaxine.Deutetrabenazine The risk or severity of QTc prolongation can be increased when Deutetrabenazine is combined with Ivosidenib.Dexamethasone The metabolism of Ivosidenib can be increased when combined with Dexamethasone.Dexamethasone ac The metabolism of Dexamethasone acetate can be increased when combined with Ivosidenib.Dexbrompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ivosidenib.Dexchlorpheniramine The metabolism of Dexchlorpheniramine maleate can be increased when combined with Ivosidenib.Dexibuprofen The metabolism of Dexibuprofen can be increased when combined with Ivosidenib.Dexlansoprazole The metabolism of Dexlansoprazole can be increased when combined with Ivosidenib.Dextromethorphan The metabolism of Dextromethorphan can be increased when combined with Ivosidenib.Dextropropoxyphene The metabolism of Dextropropoxyphene can be increased when combined with Ivosidenib.Diazepam The metabolism of Diazepam can be increased when combined with Ivosidenib.Diclofenac The metabolism of Diclofenac can be increased when combined with Ivosidenib.Dicloxacillin The metabolism of Ivosidenib can be increased when combined with Dicloxacillin.Dicoumarol The metabolism of Dicoumarol can be increased when combined with Ivosidenib.Dienogest The metabolism of Dienogest can be increased when combined with Ivosidenib.Diethylstilbestrol The metabolism of Diethylstilbestrol can be increased when combined with Ivosidenib.Difluocortolone The metabolism of Difluocortolone can be increased when combined with Ivosidenib.Difluprednate The metabolism of Difluprednate can be increased when combined with Ivosidenib.Digitoxin The metabolism of Digitoxin can be increased when combined with Ivosidenib.Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Ivosidenib.Dihydro-alpha-e The metabolism of Dihydro-alpha-ergocryptine can be increased when combined with Ivosidenib.Dihydrocodeine The metabolism of Dihydrocodeine can be increased when combined with Ivosidenib.Dihydroergocornine The metabolism of Dihydroergocornine can be increased when combined with Ivosidenib.Dihydroergocristine The metabolism of Dihydroergocristine can be increased when combined with Ivosidenib.Dihydroergotamine The metabolism of Dihydroergotamine can be increased when combined with Ivosidenib.Diltiazem The metabolism of Ivosidenib can be decreased when combined with Diltiazem.Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Ivosidenib.Dimethyl sulfoxide The metabolism of Ivosidenib can be decreased when combined with Dimethyl sulfoxide.Diosmin The metabolism of Ivosidenib can be decreased when combined with Diosmin.Diphenhydramine The metabolism of Diphenhydramine can be increased when combined with Ivosidenib.Disopyramide The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Ivosidenib.Disulfiram The metabolism of Disulfiram can be increased when combined with Ivosidenib.Docetaxel The metabolism of Docetaxel can be increased when combined with Ivosidenib.Doconexent The metabolism of Doconexent can be increased when combined with Ivosidenib.Dofetilide The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Ivosidenib.Dolasetron The metabolism of Dolasetron can be increased when combined with Ivosidenib.Domperidone The risk or severity of QTc prolongation can be increased when Domperidone is combined with Ivosidenib.Donepezil The metabolism of Donepezil can be increased when combined with Ivosidenib.Doravirine The metabolism of Doravirine can be increased when combined with Ivosidenib.Dosulepin The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Ivosidenib.Doxazosin The metabolism of Doxazosin can be increased when combined with Ivosidenib.Doxepin The metabolism of Doxepin can be increased when combined with Ivosidenib.Doxorubicin The metabolism of Doxorubicin can be increased when combined with Ivosidenib.Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ivosidenib.Dronabinol The metabolism of Dronabinol can be increased when combined with Ivosidenib.Dronedarone The risk or severity of QTc prolongation can be increased when Dronedarone is combined with Ivosidenib.Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Ivosidenib.Drospirenone The metabolism of Drospirenone can be increased when combined with Ivosidenib.Duloxetine The metabolism of Duloxetine can be increased when combined with Ivosidenib.Duvelisib The metabolism of Duvelisib can be increased when combined with Ivosidenib.Dyclonine The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Dyclonine.Dydrogesterone The metabolism of Dydrogesterone can be increased when combined with Ivosidenib.Ebastine The metabolism of Ebastine can be increased when combined with Ivosidenib.Echinacea The metabolism of Ivosidenib can be increased when combined with Echinacea.Econazole The metabolism of Ivosidenib can be decreased when combined with Econazole.Efavirenz The metabolism of Ivosidenib can be decreased when combined with Efavirenz.Elbasvir The metabolism of Elbasvir can be increased when combined with Ivosidenib.Eletriptan The metabolism of Eletriptan can be increased when combined with Ivosidenib.Elexacaftor The metabolism of Elexacaftor can be increased when combined with Ivosidenib.Eliglustat The risk or severity of QTc prolongation can be increased when Eliglustat is combined with Ivosidenib.Elvitegravir The metabolism of Ivosidenib can be decreased when combined with Elvitegravir.Emapalumab The metabolism of Ivosidenib can be increased when combined with Emapalumab.Emedastine The risk or severity of QTc prolongation can be increased when Emedastine is combined with Ivosidenib.Enasidenib The metabolism of Enasidenib can be increased when combined with Ivosidenib.Encainide The risk or severity of QTc prolongation can be increased when Encainide is combined with Ivosidenib.Encorafenib The metabolism of Encorafenib can be increased when combined with Ivosidenib.Enfortumab ve The metabolism of Enfortumab vedotin can be increased when combined with Ivosidenib.Enoxacin The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Ivosidenib.Entrectinib The metabolism of Entrectinib can be increased when combined with Ivosidenib.Enzalutamide The metabolism of Ivosidenib can be increased when combined with Enzalutamide.Epinastine The metabolism of Epinastine can be increased when combined with Ivosidenib.Epinephrine The metabolism of Ivosidenib can be decreased when combined with Epinephrine.Eplerenone The metabolism of Eplerenone can be increased when combined with Ivosidenib.Eravacycline The metabolism of Eravacycline can be increased when combined with Ivosidenib.Erdafitinib The metabolism of Erdafitinib can be increased when combined with Ivosidenib.Ergoloid mesylate The metabolism of Ergoloid mesylate can be increased when combined with Ivosidenib.Ergometrine The metabolism of Ergometrine can be increased when combined with Ivosidenib.Ergotamine The metabolism of Ivosidenib can be decreased when combined with Ergotamine.Eribulin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ivosidenib.Erlotinib The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Ivosidenib.Erythromycin The metabolism of Ivosidenib can be decreased when combined with Erythromycin.Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ivosidenib.Escitalopram The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Ivosidenib.Esketamine The metabolism of Esketamine can be increased when combined with Ivosidenib.Eslicarbazepine The metabolism of Ivosidenib can be increased when combined with Eslicarbazepine.Eslicarbazepine The metabolism of Ivosidenib can be increased when combined with Eslicarbazepine acetate.Esmolol The risk or severity of QTc prolongation can be increased when Esmolol is combined with Ivosidenib.Esomeprazole The metabolism of Esomeprazole can be increased when combined with Ivosidenib.Estazolam The metabolism of Estazolam can be increased when combined with Ivosidenib.Esterified estrogen The metabolism of Esterified estrogens can be increased when combined with Ivosidenib.Estetrol The metabolism of Estetrol can be increased when combined with Ivosidenib.Estradiol The metabolism of Estradiol can be increased when combined with Ivosidenib.Estradiol acetate The metabolism of Estradiol acetate can be increased when combined with Ivosidenib.Estradiol benzoate The metabolism of Estradiol benzoate can be increased when combined with Ivosidenib.Estradiol cypionate The metabolism of Estradiol cypionate can be increased when combined with Ivosidenib.Estradiol dienanthate The metabolism of Estradiol dienanthate can be increased when combined with Ivosidenib.Estradiol valerate The metabolism of Estradiol valerate can be increased when combined with Ivosidenib.Estramustine The metabolism of Estramustine can be increased when combined with Ivosidenib.Estrone The metabolism of Estrone can be increased when combined with Ivosidenib.Estrone sulfate The metabolism of Estrone sulfate can be increased when combined with Ivosidenib.Eszopiclone The serum concentration of Eszopiclone can be decreased when it is combined with Ivosidenib.Etanercept The metabolism of Ivosidenib can be increased when combined with Etanercept.Ethambutol The metabolism of Ivosidenib can be decreased when combined with Ethambutol.Ethanol The metabolism of Ethanol can be increased when combined with Ivosidenib.Ethinylestradiol The metabolism of Ethinylestradiol can be increased when combined with Ivosidenib.Ethosuximide The metabolism of Ethosuximide can be increased when combined with Ivosidenib.Ethyl chloride The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Ethyl chloride.Ethynodiol diace The metabolism of Ethynodiol diacetate can be increased when combined with Ivosidenib.Etidocaine The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Etidocaine.Etodolac The metabolism of Etodolac can be increased when combined with Ivosidenib.Etonogestrel The metabolism of Etonogestrel can be increased when combined with Ivosidenib.Etoposide The metabolism of Etoposide can be increased when combined with Ivosidenib.Etoricoxib The metabolism of Etoricoxib can be increased when combined with Ivosidenib.Etravirine The metabolism of Etravirine can be increased when combined with Ivosidenib.Everolimus The metabolism of Everolimus can be increased when combined with Ivosidenib.Exemestane The metabolism of Exemestane can be increased when combined with Ivosidenib.Ezogabine The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Ivosidenib.Famotidine The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ivosidenib.Fedratinib The metabolism of Fedratinib can be increased when combined with Ivosidenib.Felbamate The metabolism of Felbamate can be increased when combined with Ivosidenib.Felodipine The metabolism of Felodipine can be increased when combined with Ivosidenib.Fenofibrate The metabolism of Fenofibrate can be increased when combined with Ivosidenib.Fentanyl The metabolism of Fentanyl can be increased when combined with Ivosidenib.Fesoterodine The metabolism of Fesoterodine can be increased when combined with Ivosidenib.Fexinidazole The risk or severity of adverse effects can be increased when Ivosidenib is combined with Fexinidazole.Finasteride The metabolism of Finasteride can be increased when combined with Ivosidenib.Finerenone The metabolism of Finerenone can be increased when combined with Ivosidenib.Fish oil The metabolism of Fish oil can be increased when combined with Ivosidenib.Flecainide The risk or severity of QTc prolongation can be increased when Flecainide is combined with Ivosidenib.Flibanserin The metabolism of Flibanserin can be increased when combined with Ivosidenib.Flucloxacillin The metabolism of Ivosidenib can be increased when combined with Flucloxacillin.Fluconazole The metabolism of Ivosidenib can be decreased when combined with Fluconazole.Fludrocortisone The metabolism of Fludrocortisone can be increased when combined with Ivosidenib.Fluindione The metabolism of Fluindione can be increased when combined with Ivosidenib.Flumethasone The metabolism of Flumethasone can be increased when combined with Ivosidenib.Flunarizine The metabolism of Flunarizine can be increased when combined with Ivosidenib.Flunisolide The metabolism of Flunisolide can be increased when combined with Ivosidenib.Flunitrazepam The metabolism of Flunitrazepam can be increased when combined with Ivosidenib.Fluocinolone The metabolism of Fluocinolone acetonide can be increased when combined with Ivosidenib.Fluocinonide The metabolism of Fluocinonide can be increased when combined with Ivosidenib.Fluocortolone The metabolism of Fluocortolone can be increased when combined with Ivosidenib.Fluorometholone The metabolism of Fluorometholone can be increased when combined with Ivosidenib.Fluorouracil The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Ivosidenib.Fluoxetine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ivosidenib.Flupentixol The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Flupentixol.Fluprednisolone The metabolism of Fluprednisolone can be increased when combined with Ivosidenib.Flurandrenolide The metabolism of Flurandrenolide can be increased when combined with Ivosidenib.Flurazepam The metabolism of Flurazepam can be increased when combined with Ivosidenib.Flurbiprofen The metabolism of Flurbiprofen can be increased when combined with Ivosidenib.Fluspirilene The metabolism of Fluspirilene can be increased when combined with Ivosidenib.Flutamide The metabolism of Flutamide can be increased when combined with Ivosidenib.Fluticasone The metabolism of Fluticasone can be increased when combined with Ivosidenib.Fluticasone furoate The metabolism of Fluticasone furoate can be increased when combined with Ivosidenib.Fluticasone p The metabolism of Fluticasone propionate can be increased when combined with Ivosidenib.Fluvastatin The metabolism of Fluvastatin can be increased when combined with Ivosidenib.Fluvoxamine The metabolism of Ivosidenib can be decreased when combined with Fluvoxamine.Formestane The metabolism of Ivosidenib can be increased when combined with Formestane.Formoterol The metabolism of Formoterol can be increased when combined with Ivosidenib.Fosamprenavir The metabolism of Fosamprenavir can be increased when combined with Ivosidenib.Fosaprepitant The metabolism of Fosaprepitant can be increased when combined with Ivosidenib.Foscarnet The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Ivosidenib.Fosnetupitant The metabolism of Ivosidenib can be decreased when combined with Fosnetupitant.Fosphenytoin The metabolism of Ivosidenib can be increased when combined with Fosphenytoin.Fostamatinib The metabolism of Fostamatinib can be increased when combined with Ivosidenib.Fostemsavir The metabolism of Fostemsavir can be increased when combined with Ivosidenib.Fusidic acid The metabolism of Ivosidenib can be decreased when combined with Fusidic acid.Futibatinib The metabolism of Futibatinib can be increased when combined with Ivosidenib.Gadobenic acid The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Ivosidenib.Galantamine The metabolism of Galantamine can be increased when combined with Ivosidenib.Gatifloxacin The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Ivosidenib.Gefitinib The metabolism of Gefitinib can be increased when combined with Ivosidenib.Gemfibrozil The metabolism of Gemfibrozil can be increased when combined with Ivosidenib.Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Ivosidenib.Gestrinone The metabolism of Gestrinone can be increased when combined with Ivosidenib.Gilteritinib The metabolism of Gilteritinib can be increased when combined with Ivosidenib.Ginkgo biloba The metabolism of Ivosidenib can be decreased when combined with Ginkgo biloba.Glasdegib The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Ivosidenib.Glecaprevir The metabolism of Ivosidenib can be decreased when combined with Glecaprevir.Gliclazide The metabolism of Gliclazide can be increased when combined with Ivosidenib.Glimepiride The metabolism of Glimepiride can be increased when combined with Ivosidenib.Glipizide The metabolism of Glipizide can be increased when combined with Ivosidenib.Gliquidone The metabolism of Gliquidone can be increased when combined with Ivosidenib.Glyburide The metabolism of Glyburide can be increased when combined with Ivosidenib.Glycerol phen The metabolism of Ivosidenib can be increased when combined with Glycerol phenylbutyrate.Golimumab The metabolism of Ivosidenib can be increased when combined with Golimumab.Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ivosidenib.Granisetron The metabolism of Granisetron can be increased when combined with Ivosidenib.Grazoprevir The metabolism of Grazoprevir can be increased when combined with Ivosidenib.Grepafloxacin The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Ivosidenib.Griseofulvin The metabolism of Ivosidenib can be increased when combined with Griseofulvin.Guanfacine The metabolism of Guanfacine can be increased when combined with Ivosidenib.Halcinonide The metabolism of Halcinonide can be increased when combined with Ivosidenib.Halofantrine The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Ivosidenib.Haloperidol The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Haloperidol.Halothane The metabolism of Halothane can be increased when combined with Ivosidenib.Histrelin The risk or severity of QTc prolongation can be increased when Histrelin is combined with Ivosidenib.Hydralazine The metabolism of Ivosidenib can be decreased when combined with Hydralazine.Hydrochloroth The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Ivosidenib.Hydrocodone The metabolism of Hydrocodone can be increased when combined with Ivosidenib.Hydrocortamate The metabolism of Ivosidenib can be increased when combined with Hydrocortamate.Hydrocortisone The metabolism of Hydrocortisone can be increased when combined with Ivosidenib.Hydrocortisone acet The metabolism of Hydrocortisone acetate can be increased when combined with Ivosidenib.Hydrocortisone buty The metabolism of Hydrocortisone butyrate can be increased when combined with Ivosidenib.Hydrocortisone cyp The metabolism of Hydrocortisone cypionate can be increased when combined with Ivosidenib.Hydrocortisone phosp The metabolism of Hydrocortisone phosphate can be increased when combined with Ivosidenib.Hydrocortisone pro The metabolism of Hydrocortisone probutate can be increased when combined with Ivosidenib.Hydrocortisone suc The metabolism of Hydrocortisone succinate can be increased when combined with Ivosidenib.Hydrocortisone vale The metabolism of Hydrocortisone valerate can be increased when combined with Ivosidenib.Hydromorphone The metabolism of Hydromorphone can be increased when combined with Ivosidenib.Hydroxychloroquine The metabolism of Hydroxychloroquine can be increased when combined with Ivosidenib.Hydroxyprogesterone The metabolism of Hydroxyprogesterone caproate can be increased when combined with Ivosidenib.Hydroxyzine The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Hydroxyzine.Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ivosidenib.Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ivosidenib.Ibrexafungerp The metabolism of Ibrexafungerp can be increased when combined with Ivosidenib.Ibrutinib The metabolism of Ibrutinib can be increased when combined with Ivosidenib.Ibuprofen The metabolism of Ibuprofen can be increased when combined with Ivosidenib.Ibutilide The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Ivosidenib.Idarubicin The metabolism of Idarubicin can be increased when combined with Ivosidenib.Idelalisib The metabolism of Idelalisib can be increased when combined with Ivosidenib.Ifosfamide The metabolism of Ifosfamide can be increased when combined with Ivosidenib.Iloperidone The risk or severity of QTc prolongation can be increased when Iloperidone is combined with Ivosidenib.Imatinib The risk or severity of QTc prolongation can be increased when Imatinib is combined with Ivosidenib.Imipramine The metabolism of Imipramine can be increased when combined with Ivosidenib.Imiquimod The metabolism of Imiquimod can be increased when combined with Ivosidenib.Indacaterol The metabolism of Indacaterol can be increased when combined with Ivosidenib.Indapamide The metabolism of Indapamide can be increased when combined with Ivosidenib.Indinavir The metabolism of Ivosidenib can be decreased when combined with Indinavir.Indomethacin The metabolism of Indomethacin can be increased when combined with Ivosidenib.Infigratinib The metabolism of Infigratinib can be increased when combined with Ivosidenib.Infliximab The metabolism of Ivosidenib can be increased when combined with Infliximab.Inotersen The risk or severity of QTc prolongation can be increased when Inotersen is combined with Ivosidenib.Ipecac The metabolism of Ipecac can be increased when combined with Ivosidenib.Irbesartan The metabolism of Irbesartan can be increased when combined with Ivosidenib.Irinotecan The metabolism of Irinotecan can be increased when combined with Ivosidenib.Isavuconazole The metabolism of Ivosidenib can be decreased when combined with Isavuconazole.Isavuconazonium The metabolism of Ivosidenib can be decreased when combined with Isavuconazonium.Isoflurane The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Ivosidenib.Isoniazid The metabolism of Ivosidenib can be decreased when combined with Isoniazid.Isotretinoin The metabolism of Isotretinoin can be increased when combined with Ivosidenib.Isradipine The metabolism of Ivosidenib can be decreased when combined with Isradipine.Istradefylline The metabolism of Istradefylline can be increased when combined with Ivosidenib.Itraconazole The metabolism of Ivosidenib can be decreased when combined with Itraconazole.Ivabradine The risk or severity of QTc prolongation can be increased when Ivabradine is combined with Ivosidenib.Ivacaftor The metabolism of Ivacaftor can be increased when combined with Ivosidenib.Ivermectin The metabolism of Ivermectin can be increased when combined with Ivosidenib.Ixabepilone The metabolism of Ixabepilone can be increased when combined with Ivosidenib.Ixazomib The metabolism of Ixazomib can be increased when combined with Ivosidenib.Ketamine The metabolism of Ketamine can be increased when combined with Ivosidenib.Ketazolam The metabolism of Ketazolam can be increased when combined with Ivosidenib.Ketoconazole The metabolism of Ivosidenib can be decreased when combined with Ketoconazole.Ketorolac The metabolism of Ketorolac can be increased when combined with Ivosidenib.Lacidipine The metabolism of Lacidipine can be increased when combined with Ivosidenib.Lacosamide The metabolism of Lacosamide can be increased when combined with Ivosidenib.Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Ivosidenib.Lanreotide The metabolism of Ivosidenib can be decreased when combined with Lanreotide.Lansoprazole The metabolism of Lansoprazole can be increased when combined with Ivosidenib.Lapatinib The metabolism of Lapatinib can be increased when combined with Ivosidenib.Larotrectinib The metabolism of Larotrectinib can be increased when combined with Ivosidenib.Lefamulin Lefamulin may increase the QTc-prolonging activities of Ivosidenib.Leflunomide The metabolism of Leflunomide can be increased when combined with Ivosidenib.Lemborexant The serum concentration of Lemborexant can be decreased when it is combined with Ivosidenib.Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Ivosidenib.Lercanidipine The metabolism of Lercanidipine can be increased when combined with Ivosidenib.Lesinurad The metabolism of Lesinurad can be increased when combined with Ivosidenib.Letermovir The metabolism of Ivosidenib can be decreased when combined with Letermovir.Letrozole The metabolism of Letrozole can be increased when combined with Ivosidenib.Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ivosidenib.Levacetylmethadol The metabolism of Levacetylmethadol can be increased when combined with Ivosidenib.Levamlodipine The metabolism of Levamlodipine can be increased when combined with Ivosidenib.Levobupivacaine The metabolism of Levobupivacaine can be increased when combined with Ivosidenib.Levocabastine The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Ivosidenib.Levocetirizine The metabolism of Levocetirizine can be increased when combined with Ivosidenib.Levofloxacin The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ivosidenib.Levoketoconazole The metabolism of Ivosidenib can be decreased when combined with Levoketoconazole.Levomenthol The metabolism of Levomenthol can be increased when combined with Ivosidenib.Levomilnacipran The metabolism of Levomilnacipran can be increased when combined with Ivosidenib.Levonorgestrel The metabolism of Levonorgestrel can be increased when combined with Ivosidenib.Levosimendan The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Ivosidenib.Lidocaine The metabolism of Lidocaine can be increased when combined with Ivosidenib.Lidoflazine The metabolism of Lidoflazine can be increased when combined with Ivosidenib.Linagliptin The metabolism of Ivosidenib can be decreased when combined with Linagliptin.Liotrix The metabolism of Liotrix can be increased when combined with Ivosidenib.Lisuride The metabolism of Lisuride can be increased when combined with Ivosidenib.Lofexidine The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Ivosidenib.Lomefloxacin The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Ivosidenib.Lomitapide The metabolism of Lomitapide can be increased when combined with Ivosidenib.Lonafarnib The metabolism of Ivosidenib can be decreased when combined with Lonafarnib.Loperamide The metabolism of Loperamide can be increased when combined with Ivosidenib.Lopinavir The serum concentration of Ivosidenib can be increased when it is combined with Lopinavir.Loratadine The metabolism of Loratadine can be increased when combined with Ivosidenib.Lorazepam The metabolism of Lorazepam can be increased when combined with Ivosidenib.Lorcaserin The metabolism of Lorcaserin can be increased when combined with Ivosidenib.Lorlatinib The metabolism of Lorlatinib can be increased when combined with Ivosidenib.Lornoxicam The metabolism of Lornoxicam can be increased when combined with Ivosidenib.Lorpiprazole The metabolism of Lorpiprazole can be increased when combined with Ivosidenib.Losartan The metabolism of Losartan can be increased when combined with Ivosidenib.Lovastatin The metabolism of Ivosidenib can be decreased when combined with Lovastatin.Luliconazole The metabolism of Ivosidenib can be decreased when combined with Luliconazole.Lumacaftor The metabolism of Ivosidenib can be increased when combined with Lumacaftor.Lumateperone The serum concentration of Lumateperone can be decreased when it is combined with Ivosidenib.Lumefantrine The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Ivosidenib.Lumiracoxib The metabolism of Lumiracoxib can be increased when combined with Ivosidenib.Lurasidone The metabolism of Lurasidone can be increased when combined with Ivosidenib.Lurbinectedin The metabolism of Lurbinectedin can be increased when combined with Ivosidenib.Lynestrenol The metabolism of Lynestrenol can be increased when combined with Ivosidenib.Macimorelin The risk or severity of QTc prolongation can be increased when Macimorelin is combined with Ivosidenib.Macitentan The metabolism of Macitentan can be increased when combined with Ivosidenib.Manidipine The metabolism of Manidipine can be increased when combined with Ivosidenib.Maprotiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Ivosidenib.Maraviroc The metabolism of Maraviroc can be increased when combined with Ivosidenib.Maribavir The metabolism of Maribavir can be increased when combined with Ivosidenib.Mavacamten The serum concentration of Ivosidenib can be decreased when it is combined with Mavacamten.Medrogestone The metabolism of Medrogestone can be increased when combined with Ivosidenib.Medroxyprogester The metabolism of Medroxyprogesterone acetate can be increased when combined with Ivosidenib.Medrysone The metabolism of Medrysone can be increased when combined with Ivosidenib.Mefenamic acid The metabolism of Mefenamic acid can be increased when combined with Ivosidenib.Mefloquine The metabolism of Mefloquine can be increased when combined with Ivosidenib.Megestrol acetate The metabolism of Megestrol acetate can be increased when combined with Ivosidenib.Meloxicam The metabolism of Meloxicam can be increased when combined with Ivosidenib.Meperidine The metabolism of Meperidine can be increased when combined with Ivosidenib.Mephenytoin The metabolism of Mephenytoin can be increased when combined with Ivosidenib.Mepivacaine The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Mepivacaine.Meprednisone The metabolism of Meprednisone can be increased when combined with Ivosidenib.Mepyramine The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Ivosidenib.Mesoridazine The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Ivosidenib.Mestranol The metabolism of Mestranol can be increased when combined with Ivosidenib.Methadone The metabolism of Methadone can be increased when combined with Ivosidenib.Methimazole The metabolism of Ivosidenib can be decreased when combined with Methimazole.Methotrexate The metabolism of Methotrexate can be increased when combined with Ivosidenib.Methotrimeprazine The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Ivosidenib.Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ivosidenib.Methoxyflurane The metabolism of Methoxyflurane can be increased when combined with Ivosidenib.Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Ivosidenib.Methylene blue The metabolism of Ivosidenib can be decreased when combined with Methylene blue.Methylergometrine The metabolism of Methylergometrine can be increased when combined with Ivosidenib.Methylphenobarbital The metabolism of Ivosidenib can be increased when combined with Methylphenobarbital.Methylprednisolone The metabolism of Methylprednisolone can be increased when combined with Ivosidenib.Methylprednisone The metabolism of Methylprednisone can be increased when combined with Ivosidenib.Methyltestosterone The metabolism of Methyltestosterone can be increased when combined with Ivosidenib.Methysergide The metabolism of Methysergide can be increased when combined with Ivosidenib.Metoclopramide The metabolism of Metoclopramide can be increased when combined with Ivosidenib.Metreleptin The metabolism of Ivosidenib can be increased when combined with Metreleptin.Metronidazole The metabolism of Ivosidenib can be decreased when combined with Metronidazole.Metyrapone The metabolism of Ivosidenib can be increased when combined with Metyrapone.Mexiletine The metabolism of Mexiletine can be increased when combined with Ivosidenib.Mianserin The metabolism of Mianserin can be increased when combined with Ivosidenib.Miconazole The metabolism of Ivosidenib can be decreased when combined with Miconazole.Midazolam The metabolism of Midazolam can be increased when combined with Ivosidenib.Midostaurin The metabolism of Ivosidenib can be increased when combined with Midostaurin.Mifepristone The risk or severity of QTc prolongation can be increased when Mifepristone is combined with Ivosidenib.Milnacipran The metabolism of Ivosidenib can be decreased when combined with Milnacipran.Miocamycin The metabolism of Ivosidenib can be decreased when combined with Miocamycin.Mirabegron The metabolism of Mirabegron can be increased when combined with Ivosidenib.Mirtazapine The metabolism of Mirtazapine can be increased when combined with Ivosidenib.Mitapivat The metabolism of Mitapivat can be increased when combined with Ivosidenib.Mitotane The metabolism of Ivosidenib can be increased when combined with Mitotane.Mizolastine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Ivosidenib.Mobocertinib The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Mobocertinib.Modafinil The metabolism of Modafinil can be increased when combined with Ivosidenib.Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Ivosidenib.Mometasone The metabolism of Mometasone furoate can be increased when combined with Ivosidenib.Montelukast The metabolism of Montelukast can be increased when combined with Ivosidenib.Moricizine The risk or severity of QTc prolongation can be increased when Moricizine is combined with Ivosidenib.Morphine The metabolism of Morphine can be increased when combined with Ivosidenib.Mosunetuzumab The metabolism of Ivosidenib can be decreased when combined with Mosunetuzumab.Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ivosidenib.Mycophenolate m The metabolism of Mycophenolate mofetil can be increased when combined with Ivosidenib.Nabilone The metabolism of Nabilone can be increased when combined with Ivosidenib.Nabumetone The metabolism of Nabumetone can be increased when combined with Ivosidenib.Nafcillin The metabolism of Ivosidenib can be increased when combined with Nafcillin.Nalidixic acid The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Ivosidenib.Naloxegol The metabolism of Naloxegol can be increased when combined with Ivosidenib.Naproxen The metabolism of Naproxen can be increased when combined with Ivosidenib.Nateglinide The metabolism of Nateglinide can be increased when combined with Ivosidenib.Nebivolol The metabolism of Nebivolol can be increased when combined with Ivosidenib.Nefazodone The metabolism of Ivosidenib can be decreased when combined with Nefazodone.Nelfinavir The metabolism of Ivosidenib can be decreased when combined with Nelfinavir.Neratinib The metabolism of Neratinib can be increased when combined with Ivosidenib.Netupitant The metabolism of Ivosidenib can be decreased when combined with Netupitant.Nevirapine The metabolism of Nevirapine can be increased when combined with Ivosidenib.Niacin The metabolism of Ivosidenib can be decreased when combined with Niacin.Nicardipine The metabolism of Ivosidenib can be decreased when combined with Nicardipine.Niclosamide The metabolism of Niclosamide can be increased when combined with Ivosidenib.Nifedipine The metabolism of Nifedipine can be increased when combined with Ivosidenib.Nilotinib The risk or severity of QTc prolongation can be increased when Nilotinib is combined with Ivosidenib.Nilvadipine The metabolism of Ivosidenib can be decreased when combined with Nilvadipine.Nimesulide The metabolism of Nimesulide can be increased when combined with Ivosidenib.Nimodipine The metabolism of Nimodipine can be increased when combined with Ivosidenib.Nintedanib The metabolism of Nintedanib can be increased when combined with Ivosidenib.Nirmatrelvir The metabolism of Nirmatrelvir can be increased when combined with Ivosidenib.Nisoldipine The metabolism of Nisoldipine can be increased when combined with Ivosidenib.Nitrazepam The metabolism of Nitrazepam can be increased when combined with Ivosidenib.Nitrendipine The metabolism of Nitrendipine can be increased when combined with Ivosidenib.Nomegestrol The metabolism of Nomegestrol can be increased when combined with Ivosidenib.Nomegestrol aceta The metabolism of Nomegestrol acetate can be increased when combined with Ivosidenib.Norelgestromin The metabolism of Norelgestromin can be increased when combined with Ivosidenib.Norethisterone The metabolism of Norethisterone can be increased when combined with Ivosidenib.Norethynodrel The metabolism of Norethynodrel can be increased when combined with Ivosidenib.Norfloxacin The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Ivosidenib.Norgestimate The metabolism of Norgestimate can be increased when combined with Ivosidenib.Norgestrel The metabolism of Norgestrel can be increased when combined with Ivosidenib.Nortriptyline The metabolism of Nortriptyline can be increased when combined with Ivosidenib.Noscapine The metabolism of Ivosidenib can be decreased when combined with Noscapine.Nylidrin The metabolism of Nylidrin can be increased when combined with Ivosidenib.Octreotide The serum concentration of Ivosidenib can be increased when it is combined with Octreotide.Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Ivosidenib.Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Ivosidenib.Olaparib The metabolism of Olaparib can be increased when combined with Ivosidenib.Oliceridine The serum concentration of Oliceridine can be decreased when it is combined with Ivosidenib.Olodaterol The metabolism of Olodaterol can be increased when combined with Ivosidenib.Omeprazole The metabolism of Omeprazole can be increased when combined with Ivosidenib.Ondansetron The metabolism of Ondansetron can be increased when combined with Ivosidenib.Opium The metabolism of Opium can be increased when combined with Ivosidenib.Oritavancin The metabolism of Ivosidenib can be increased when combined with Oritavancin.Orphenadrine The metabolism of Orphenadrine can be increased when combined with Ivosidenib.Osilodrostat The metabolism of Osilodrostat can be increased when combined with Ivosidenib.Osimertinib The metabolism of Osimertinib can be increased when combined with Ivosidenib.Ospemifene The metabolism of Ospemifene can be increased when combined with Ivosidenib.Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ivosidenib.Oxatomide The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Ivosidenib.Oxcarbazepine The metabolism of Ivosidenib can be increased when combined with Oxcarbazepine.Oxetacaine The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Oxetacaine.Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Oxybuprocaine.Oxybutynin The metabolism of Oxybutynin can be increased when combined with Ivosidenib.Oxycodone The metabolism of Oxycodone can be increased when combined with Ivosidenib.Oxymorphone The metabolism of Oxymorphone can be increased when combined with Ivosidenib.Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ivosidenib.Paclitaxel The metabolism of Paclitaxel can be increased when combined with Ivosidenib.Pacritinib The serum concentration of Ivosidenib can be increased when it is combined with Pacritinib.Palbociclib The metabolism of Palbociclib can be increased when combined with Ivosidenib.Paliperidone The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Ivosidenib.Palonosetron The metabolism of Palonosetron can be increased when combined with Ivosidenib.Palovarotene The metabolism of Palovarotene can be increased when combined with Ivosidenib.Panobinostat The metabolism of Panobinostat can be increased when combined with Ivosidenib.Pantoprazole The metabolism of Pantoprazole can be increased when combined with Ivosidenib.Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ivosidenib.Paramethadione The metabolism of Paramethadione can be increased when combined with Ivosidenib.Parecoxib The metabolism of Parecoxib can be increased when combined with Ivosidenib.Paricalcitol The metabolism of Paricalcitol can be increased when combined with Ivosidenib.Paritaprevir The metabolism of Paritaprevir can be increased when combined with Ivosidenib.Paroxetine The metabolism of Paroxetine can be increased when combined with Ivosidenib.Pasireotide The metabolism of Ivosidenib can be decreased when combined with Pasireotide.Pazopanib The metabolism of Pazopanib can be increased when combined with Ivosidenib.Pefloxacin The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Ivosidenib.Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Ivosidenib.Pemigatinib The metabolism of Pemigatinib can be increased when combined with Ivosidenib.Pentamidine The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Ivosidenib.Pentobarbital The metabolism of Ivosidenib can be increased when combined with Pentobarbital.Perampanel The metabolism of Perampanel can be increased when combined with Ivosidenib.Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with Ivosidenib.Perhexiline The metabolism of Perhexiline can be increased when combined with Ivosidenib.Pexidartinib The metabolism of Pexidartinib can be increased when combined with Ivosidenib.Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ivosidenib.Phenobarbital The metabolism of Ivosidenib can be increased when combined with Phenobarbital.Phenol The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Phenol.Phenprocoumon The metabolism of Phenprocoumon can be increased when combined with Ivosidenib.Phentermine The metabolism of Phentermine can be increased when combined with Ivosidenib.Phenylbutazone The metabolism of Phenylbutazone can be increased when combined with Ivosidenib.Phenytoin The metabolism of Ivosidenib can be increased when combined with Phenytoin.Pimavanserin The metabolism of Pimavanserin can be increased when combined with Ivosidenib.Pimecrolimus The metabolism of Pimecrolimus can be increased when combined with Ivosidenib.Pimozide The risk or severity of QTc prolongation can be increased when Pimozide is combined with Ivosidenib.Pinacidil The metabolism of Pinacidil can be increased when combined with Ivosidenib.Pinaverium The metabolism of Pinaverium can be increased when combined with Ivosidenib.Pioglitazone The metabolism of Pioglitazone can be increased when combined with Ivosidenib.Piperaquine The metabolism of Piperaquine can be increased when combined with Ivosidenib.Pipotiazine The metabolism of Pipotiazine can be increased when combined with Ivosidenib.Pirfenidone The metabolism of Pirfenidone can be increased when combined with Ivosidenib.Piroxicam The metabolism of Piroxicam can be increased when combined with Ivosidenib.Pitavastatin The metabolism of Pitavastatin can be increased when combined with Ivosidenib.Pitolisant The serum concentration of Ivosidenib can be decreased when it is combined with Pitolisant.Polatuzumab ve The metabolism of Polatuzumab vedotin can be increased when combined with Ivosidenib.Pomalidomide The metabolism of Pomalidomide can be increased when combined with Ivosidenib.Ponatinib The metabolism of Ponatinib can be increased when combined with Ivosidenib.Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Ivosidenib.Posaconazole The metabolism of Ivosidenib can be decreased when combined with Posaconazole.Pralsetinib The metabolism of Pralsetinib can be increased when combined with Ivosidenib.Pramocaine The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Pramocaine.Prasterone The metabolism of Prasterone can be increased when combined with Ivosidenib.Prasugrel The metabolism of Prasugrel can be increased when combined with Ivosidenib.Prazepam The metabolism of Prazepam can be increased when combined with Ivosidenib.Praziquantel The metabolism of Praziquantel can be increased when combined with Ivosidenib.Prednicarbate The metabolism of Prednicarbate can be increased when combined with Ivosidenib.Prednisolone The metabolism of Prednisolone can be increased when combined with Ivosidenib.Prednisolone ace The metabolism of Prednisolone acetate can be increased when combined with Ivosidenib.Prednisolone p The metabolism of Prednisolone phosphate can be increased when combined with Ivosidenib.Prednisone The metabolism of Prednisone can be increased when combined with Ivosidenib.Prednisone acetate The metabolism of Ivosidenib can be increased when combined with Prednisone acetate.Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ivosidenib.Pregnenolone The metabolism of Pregnenolone can be increased when combined with Ivosidenib.Prenylamine The metabolism of Prenylamine can be increased when combined with Ivosidenib.Pretomanid The metabolism of Pretomanid can be increased when combined with Ivosidenib.Prilocaine The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Prilocaine.Primaquine The metabolism of Ivosidenib can be decreased when combined with Primaquine.Primidone The metabolism of Ivosidenib can be increased when combined with Primidone.Probenecid The metabolism of Ivosidenib can be increased when combined with Probenecid.Probucol The risk or severity of QTc prolongation can be increased when Probucol is combined with Ivosidenib.Procainamide The risk or severity of QTc prolongation can be increased when Procainamide is combined with Ivosidenib.Procaine The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Procaine.Prochlorperazine The metabolism of Prochlorperazine can be increased when combined with Ivosidenib.Progesterone The metabolism of Progesterone can be increased when combined with Ivosidenib.Proguanil The metabolism of Proguanil can be increased when combined with Ivosidenib.Promazine The metabolism of Promazine can be increased when combined with Ivosidenib.Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Ivosidenib.Propafenone The metabolism of Propafenone can be increased when combined with Ivosidenib.Proparacaine The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Proparacaine.Propiverine The metabolism of Propiverine can be increased when combined with Ivosidenib.Propofol The metabolism of Propofol can be increased when combined with Ivosidenib.Propoxycaine The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Propoxycaine.Propranolol The metabolism of Propranolol can be increased when combined with Ivosidenib.Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Ivosidenib.Prucalopride The metabolism of Prucalopride can be increased when combined with Ivosidenib.Quazepam The metabolism of Quazepam can be increased when combined with Ivosidenib.Quetiapine The metabolism of Quetiapine can be increased when combined with Ivosidenib.Quinidine The risk or severity of QTc prolongation can be increased when Quinidine is combined with Ivosidenib.Quinine The risk or severity of QTc prolongation can be increased when Quinine is combined with Ivosidenib.Quinupristin The metabolism of Ivosidenib can be decreased when combined with Quinupristin.Raloxifene The metabolism of Ivosidenib can be decreased when combined with Raloxifene.Ramelteon The metabolism of Ramelteon can be increased when combined with Ivosidenib.Ranolazine The metabolism of Ranolazine can be increased when combined with Ivosidenib.Reboxetine The metabolism of Reboxetine can be increased when combined with Ivosidenib.Regorafenib The metabolism of Regorafenib can be increased when combined with Ivosidenib.Relugolix The metabolism of Relugolix can be increased when combined with Ivosidenib.Remdesivir The metabolism of Remdesivir can be increased when combined with Ivosidenib.Repaglinide The metabolism of Repaglinide can be increased when combined with Ivosidenib.Retapamulin The metabolism of Retapamulin can be increased when combined with Ivosidenib.Ribociclib The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Ivosidenib.Rifabutin The metabolism of Rifabutin can be increased when combined with Ivosidenib.Rifampicin The metabolism of Ivosidenib can be increased when combined with Rifampicin.Rifamycin The metabolism of Ivosidenib can be increased when combined with Rifamycin.Rifapentine The metabolism of Ivosidenib can be increased when combined with Rifapentine.Rilonacept The metabolism of Ivosidenib can be increased when combined with Rilonacept.Rilpivirine The metabolism of Rilpivirine can be increased when combined with Ivosidenib.Rimegepant The metabolism of Rimegepant can be increased when combined with Ivosidenib.Rimexolone The metabolism of Ivosidenib can be increased when combined with Rimexolone.Rimonabant The metabolism of Rimonabant can be increased when combined with Ivosidenib.Riociguat The metabolism of Riociguat can be increased when combined with Ivosidenib.Ripretinib The metabolism of Ripretinib can be increased when combined with Ivosidenib.Risperidone The metabolism of Risperidone can be increased when combined with Ivosidenib.Ritonavir The serum concentration of Ivosidenib can be increased when it is combined with Ritonavir.Rivaroxaban The metabolism of Rivaroxaban can be increased when combined with Ivosidenib.Rofecoxib The metabolism of Rofecoxib can be increased when combined with Ivosidenib.Roflumilast The metabolism of Roflumilast can be increased when combined with Ivosidenib.Rolapitant The metabolism of Rolapitant can be increased when combined with Ivosidenib.Romidepsin The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Ivosidenib.Ropivacaine The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Ropivacaine.Rosiglitazone The metabolism of Rosiglitazone can be increased when combined with Ivosidenib.Rosoxacin The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Ivosidenib.Rosuvastatin The metabolism of Rosuvastatin can be increased when combined with Ivosidenib.Rotigotine The metabolism of Rotigotine can be increased when combined with Ivosidenib.Roxithromycin The metabolism of Roxithromycin can be increased when combined with Ivosidenib.Rucaparib The metabolism of Rucaparib can be increased when combined with Ivosidenib.Rufinamide The metabolism of Ivosidenib can be increased when combined with Rufinamide.Rupatadine The metabolism of Rupatadine can be increased when combined with Ivosidenib.Ruxolitinib The metabolism of Ruxolitinib can be increased when combined with Ivosidenib.Safinamide The metabolism of Safinamide can be increased when combined with Ivosidenib.Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ivosidenib.Salicylic acid The metabolism of Salicylic acid can be increased when combined with Ivosidenib.Salmeterol The metabolism of Salmeterol can be increased when combined with Ivosidenib.Samidorphan The metabolism of Samidorphan can be increased when combined with Ivosidenib.Saquinavir The metabolism of Ivosidenib can be decreased when combined with Saquinavir.Sarilumab The metabolism of Ivosidenib can be increased when combined with Sarilumab.Satralizumab The serum concentration of Ivosidenib can be decreased when it is combined with Satralizumab.Saxagliptin The metabolism of Saxagliptin can be increased when combined with Ivosidenib.Scopolamine The metabolism of Scopolamine can be increased when combined with Ivosidenib.Secobarbital The metabolism of Ivosidenib can be increased when combined with Secobarbital.Secukinumab The metabolism of Ivosidenib can be increased when combined with Secukinumab.Segesterone ac The metabolism of Segesterone acetate can be increased when combined with Ivosidenib.Selegiline The metabolism of Selegiline can be increased when combined with Ivosidenib.Selexipag The metabolism of Selexipag can be increased when combined with Ivosidenib.Selinexor The metabolism of Selinexor can be increased when combined with Ivosidenib.Selpercatinib The serum concentration of Selpercatinib can be decreased when it is combined with Ivosidenib.Selumetinib The metabolism of Selumetinib can be increased when combined with Ivosidenib.Sertindole The metabolism of Sertindole can be increased when combined with Ivosidenib.Sertraline The metabolism of Sertraline can be increased when combined with Ivosidenib.Sevoflurane The metabolism of Sevoflurane can be increased when combined with Ivosidenib.Sibutramine The metabolism of Sibutramine can be increased when combined with Ivosidenib.Sildenafil The metabolism of Sildenafil can be increased when combined with Ivosidenib.Silodosin The metabolism of Silodosin can be increased when combined with Ivosidenib.Siltuximab The metabolism of Ivosidenib can be increased when combined with Siltuximab.Simeprevir The metabolism of Ivosidenib can be decreased when combined with Simeprevir.Simvastatin The metabolism of Simvastatin can be increased when combined with Ivosidenib.Siponimod The metabolism of Siponimod can be increased when combined with Ivosidenib.Sirolimus The metabolism of Sirolimus can be increased when combined with Ivosidenib.Sitagliptin The metabolism of Sitagliptin can be increased when combined with Ivosidenib.Sitaxentan The metabolism of Sitaxentan can be increased when combined with Ivosidenib.Solifenacin The metabolism of Solifenacin can be increased when combined with Ivosidenib.Somatostatin The metabolism of Ivosidenib can be decreased when combined with Somatostatin.Somatrogon The metabolism of Ivosidenib can be increased when combined with Somatrogon.Sonidegib The metabolism of Sonidegib can be increased when combined with Ivosidenib.Sorafenib The metabolism of Sorafenib can be increased when combined with Ivosidenib.Sotalol The risk or severity of QTc prolongation can be increased when Sotalol is combined with Ivosidenib.Sotorasib The serum concentration of Ivosidenib can be decreased when it is combined with Sotorasib.Sparfloxacin The risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Ivosidenib.St. John's Wort The metabolism of Ivosidenib can be increased when combined with St. John's Wort.Stiripentol The metabolism of Ivosidenib can be decreased when combined with Stiripentol.Sufentanil The metabolism of Sufentanil can be increased when combined with Ivosidenib.Sulfadiazine The metabolism of Sulfadiazine can be increased when combined with Ivosidenib.Sulfamethoxazole The metabolism of Sulfamethoxazole can be increased when combined with Ivosidenib.Sulfinpyrazone The metabolism of Sulfinpyrazone can be increased when combined with Ivosidenib.Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Ivosidenib.Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Ivosidenib.Sultopride The risk or severity of QTc prolongation can be increased when Sultopride is combined with Ivosidenib.Sunitinib The metabolism of Sunitinib can be increased when combined with Ivosidenib.Suprofen The metabolism of Suprofen can be increased when combined with Ivosidenib.Suvorexant The metabolism of Suvorexant can be increased when combined with Ivosidenib.SynEstrogens, A The metabolism of Synthetic Conjugated Estrogens, A can be increased when combined with Ivosidenib.SyEstrogens, B The metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Ivosidenib.Tacrolimus The metabolism of Tacrolimus can be increased when combined with Ivosidenib.Tadalafil The metabolism of Tadalafil can be increased when combined with Ivosidenib.Tamoxifen The metabolism of Tamoxifen can be increased when combined with Ivosidenib.Tamsulosin The metabolism of Tamsulosin can be increased when combined with Ivosidenib.Tasimelteon The metabolism of Tasimelteon can be increased when combined with Ivosidenib.Tazemetostat The metabolism of Tazemetostat can be increased when combined with Ivosidenib.Tecovirimat The metabolism of Ivosidenib can be increased when combined with Tecovirimat.Telaprevir The metabolism of Ivosidenib can be decreased when combined with Telaprevir.Telavancin The risk or severity of QTc prolongation can be increased when Telavancin is combined with Ivosidenib.Telithromycin The metabolism of Ivosidenib can be decreased when combined with Telithromycin.Telotristat ethyl The serum concentration of Ivosidenib can be decreased when it is combined with Telotristat ethyl.Temsirolimus The metabolism of Temsirolimus can be increased when combined with Ivosidenib.Teniposide The metabolism of Teniposide can be increased when combined with Ivosidenib.Tenofovir alafe The metabolism of Tenofovir alafenamide can be increased when combined with Ivosidenib.Tenoxicam The metabolism of Tenoxicam can be increased when combined with Ivosidenib.Tepotinib The metabolism of Tepotinib can be increased when combined with Ivosidenib.Terbinafine The metabolism of Terbinafine can be increased when combined with Ivosidenib.Terbutaline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Ivosidenib.Terfenadine The risk or severity of QTc prolongation can be increased when Terfenadine is combined with Ivosidenib.Terlipressin The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Ivosidenib.Testosterone The metabolism of Testosterone can be increased when combined with Ivosidenib.Testosterone cyp The metabolism of Testosterone cypionate can be increased when combined with Ivosidenib.Testosterone enan The metabolism of Testosterone enanthate can be increased when combined with Ivosidenib.Testosterone pro The metabolism of Testosterone propionate can be increased when combined with Ivosidenib.Tetrabenazine The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Ivosidenib.Tetracaine The risk or severity of methemoglobinemia can be increased when Ivosidenib is combined with Tetracaine.Tetracycline The metabolism of Tetracycline can be increased when combined with Ivosidenib.Tezacaftor The metabolism of Tezacaftor can be increased when combined with Ivosidenib.Thalidomide The metabolism of Thalidomide can be increased when combined with Ivosidenib.Theophylline The metabolism of Theophylline can be increased when combined with Ivosidenib.Thiamylal The metabolism of Thiamylal can be increased when combined with Ivosidenib.Thioridazine The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Ivosidenib.Thiotepa The metabolism of Thiotepa can be increased when combined with Ivosidenib.Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Ivosidenib.Tiagabine The metabolism of Tiagabine can be increased when combined with Ivosidenib.Ticagrelor The metabolism of Ticagrelor can be increased when combined with Ivosidenib.Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Ivosidenib.Tinidazole The metabolism of Tinidazole can be increased when combined with Ivosidenib.Tioconazole The metabolism of Ivosidenib can be decreased when combined with Tioconazole.Tiotropium The metabolism of Tiotropium can be increased when combined with Ivosidenib.Tipranavir The metabolism of Ivosidenib can be decreased when combined with Tipranavir.Tisotumab vedotin The metabolism of Tisotumab vedotin can be increased when combined with Ivosidenib.Tivozanib The metabolism of Tivozanib can be increased when combined with Ivosidenib.Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Ivosidenib.Tocilizumab The metabolism of Ivosidenib can be increased when combined with Tocilizumab.Tocofersolan The metabolism of Tocofersolan can be increased when combined with Ivosidenib.Tocopherol The metabolism of Tocopherol can be increased when combined with Ivosidenib.Tofacitinib The metabolism of Tofacitinib can be increased when combined with Ivosidenib.Tolazamide The metabolism of Tolazamide can be increased when combined with Ivosidenib.Tolbutamide The metabolism of Tolbutamide can be increased when combined with Ivosidenib.Tolfenamic acid The metabolism of Tolfenamic acid can be increased when combined with Ivosidenib.Tolterodine The metabolism of Tolterodine can be increased when combined with Ivosidenib.Tolvaptan The metabolism of Tolvaptan can be increased when combined with Ivosidenib.Topiramate The metabolism of Ivosidenib can be increased when combined with Topiramate.Torasemide The metabolism of Torasemide can be increased when combined with Ivosidenib.Toremifene The risk or severity of QTc prolongation can be increased when Toremifene is combined with Ivosidenib.Trabectedin The metabolism of Trabectedin can be increased when combined with Ivosidenib.Tramadol The metabolism of Tramadol can be increased when combined with Ivosidenib.Trastuzumab emte The metabolism of Trastuzumab emtansine can be increased when combined with Ivosidenib.Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ivosidenib.Treprostinil The metabolism of Treprostinil can be increased when combined with Ivosidenib.Tretinoin The metabolism of Tretinoin can be increased when combined with Ivosidenib.Triamcinolone The metabolism of Triamcinolone can be increased when combined with Ivosidenib.Triazolam The metabolism of Triazolam can be increased when combined with Ivosidenib.Triclabendazole The metabolism of Triclabendazole can be increased when combined with Ivosidenib.Trimebutine The metabolism of Trimebutine can be increased when combined with Ivosidenib.Trimethadione The metabolism of Trimethadione can be increased when combined with Ivosidenib.Trimethoprim The metabolism of Trimethoprim can be increased when combined with Ivosidenib.Trimipramine The metabolism of Trimipramine can be increased when combined with Ivosidenib.Triprolidine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Ivosidenib.Triptorelin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ivosidenib.Troglitazone The metabolism of Troglitazone can be increased when combined with Ivosidenib.Troleandomycin The metabolism of Ivosidenib can be decreased when combined with Troleandomycin.Trovafloxacin The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Ivosidenib.Tucatinib The metabolism of Tucatinib can be decreased when combined with Ivosidenib.Ubrogepant The metabolism of Ubrogepant can be increased when combined with Ivosidenib.Udenafil The metabolism of Udenafil can be increased when combined with Ivosidenib.Ulipristal The metabolism of Ulipristal can be increased when combined with Ivosidenib.Upadacitinib The metabolism of Upadacitinib can be increased when combined with Ivosidenib.Valbenazine The metabolism of Valbenazine can be increased when combined with Ivosidenib.Valdecoxib The metabolism of Valdecoxib can be increased when combined with Ivosidenib.Valproic acid The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Ivosidenib.Valsartan The metabolism of Valsartan can be increased when combined with Ivosidenib.Vandetanib The risk or severity of QTc prolongation can be increased when Vandetanib is combined with Ivosidenib.Vardenafil The metabolism of Vardenafil can be increased when combined with Ivosidenib.Velpatasvir The metabolism of Velpatasvir can be increased when combined with Ivosidenib.Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ivosidenib.Venetoclax The metabolism of Ivosidenib can be decreased when combined with Venetoclax.Venlafaxine The metabolism of Venlafaxine can be increased when combined with Ivosidenib.Verapamil The metabolism of Ivosidenib can be decreased when combined with Verapamil.Vernakalant The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Ivosidenib.Vilanterol The metabolism of Vilanterol can be increased when combined with Ivosidenib.Vilazodone The metabolism of Vilazodone can be increased when combined with Ivosidenib.Viloxazine The metabolism of Ivosidenib can be decreased when combined with Viloxazine.Vinblastine The metabolism of Vinblastine can be increased when combined with Ivosidenib.Vincristine The metabolism of Vincristine can be increased when combined with Ivosidenib.Vindesine The metabolism of Vindesine can be increased when combined with Ivosidenib.Vinflunine The metabolism of Vinflunine can be increased when combined with Ivosidenib.Vinorelbine The metabolism of Vinorelbine can be increased when combined with Ivosidenib.Vismodegib The metabolism of Vismodegib can be increased when combined with Ivosidenib.Vitamin D The metabolism of Vitamin D can be increased when combined with Ivosidenib.Vitamin E The metabolism of Vitamin E can be increased when combined with Ivosidenib.Voclosporin The metabolism of Voclosporin can be increased when combined with Ivosidenib.Vonoprazan The metabolism of Vonoprazan can be increased when combined with Ivosidenib.Vorapaxar The metabolism of Vorapaxar can be increased when combined with Ivosidenib.Voriconazole The metabolism of Ivosidenib can be decreased when combined with Voriconazole.Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Ivosidenib.Vortioxetine The metabolism of Vortioxetine can be increased when combined with Ivosidenib.Voxelotor The serum concentration of Ivosidenib can be increased when it is combined with Voxelotor.Voxilaprevir The metabolism of Voxilaprevir can be increased when combined with Ivosidenib.Warfarin The metabolism of Warfarin can be increased when combined with Ivosidenib.Ximelagatran The metabolism of Ximelagatran can be increased when combined with Ivosidenib.Yohimbine The metabolism of Yohimbine can be increased when combined with Ivosidenib.Zafirlukast The metabolism of Zafirlukast can be increased when combined with Ivosidenib.Zaleplon The metabolism of Zaleplon can be increased when combined with Ivosidenib.Zanubrutinib The metabolism of Zanubrutinib can be increased when combined with Ivosidenib.Zidovudine The metabolism of Zidovudine can be increased when combined with Ivosidenib.Zileuton The metabolism of Zileuton can be increased when combined with Ivosidenib.Zimelidine The metabolism of Ivosidenib can be decreased when combined with Zimelidine.Ziprasidone The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Ziprasidone.Zolpidem The metabolism of Zolpidem can be increased when combined with Ivosidenib.Zonisamide The metabolism of Zonisamide can be increased when combined with Ivosidenib.Zopiclone The metabolism of Zopiclone can be increased when combined with Ivosidenib.Zotepine The metabolism of Zotepine can be increased when combined with Ivosidenib.Zuclopenthixol The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Ivosidenib.Pregnancy and Lactation US FDA pregnancy category: Not assigned. Pregnancy Based on animal embryo-fetal toxicity studies, TIBSOVO may cause fetal harm when administered to a pregnant woman. There are no available data on TIBSOVO use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. In animal embryo-fetal toxicity studies, oral administration of ivosidenib to pregnant rats and rabbits during organogenesis was associated with embryo-fetal mortality and alterations to growth starting at 2 times the steady-state clinical exposure based on the AUC at the recommended human dose (see Data). If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, advise the patient of the potential risk to a fetus. Lactation There are no data on the presence of ivosidenib or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Because many drugs are excreted in human milk and because of the potential for adverse reactions in breastfed children, advise women not to breastfeed during treatment with TIBSOVO and for at least 1 month after the last dose.Why is this medication prescribed?

Ivosidenib is used to treat a certain type of acute myeloid leukemia (AML; a type of cancer that begins in the white blood cells) that has returned or that has not improved after previous treatment(s). Ivosidenib is also used alone or in combination with azacitidine (Onureg) to treat a certain type of AML in some adults older than 75 years of age as a first treatment. Ivosidenib is also used in adults who have already received previous treatment(s) to treat…

How should this medicine be used?

Ivosidenib comes as a tablet to take by mouth. It is usually taken with or without food once daily. Do not take it with high-fat food such as eggs, butter, whole-milk dairy products (such as whole milk, cheese, and yogurt), fried foods, or fast food. Take ivosidenib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take ivosidenib exactly as directed.…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area later with a custom field named _rx_references.

Related Articles

Vasodilator Drugs

June 9, 20258 min read5 views

Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   Vasodilators are medicines…

Read more

Written by Dr. Harun Ar Rashid, MD - Arthritis, Bones, Joints Pain, Trauma, and Internal Medicine Specialist

Dr. Md. Harun Ar Rashid, MPH, MD, PhD, is a highly respected medical specialist celebrated for his exceptional clinical expertise and unwavering commitment to patient care. With advanced qualifications including MPH, MD, and PhD, he integrates cutting-edge research with a compassionate approach to medicine, ensuring that every patient receives personalized and effective treatment. His extensive training and hands-on experience enable him to diagnose complex conditions accurately and develop innovative treatment strategies tailored to individual needs. In addition to his clinical practice, Dr. Harun Ar Rashid is dedicated to medical education and research, writing and inventory creative thinking, innovative idea, critical care managementing make in his community to outreach, often participating in initiatives that promote health awareness and advance medical knowledge. His career is a testament to the high standards represented by his credentials, and he continues to contribute significantly to his field, driving improvements in both patient outcomes and healthcare practices. Born and educated in Bangladesh, Dr. Rashid earned his BPT from the University of Dhaka before pursuing postgraduate training internationally. He completed his MD in Internal Medicine at King’s College London, where he developed a special interest in inflammatory arthritis and metabolic bone disease. He then undertook a PhD in Orthopedic Science at the University of Oxford, conducting pioneering research on cytokine signaling pathways in rheumatoid arthritis. Following his doctoral studies, Dr. Rashid returned to clinical work with a fellowship in interventional pain management at the Rx University School of Medicine, refining his skills in image-guided joint injections and minimally invasive pain-relief techniques.